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1 SUMMARY 
This thesis focuses on the design, synthesis and evaluation of novel functionalized 
photochromic dithienylethenes (DTEs) for applications in biology. 
Chapter 1 deals with the creation of dithienylcyclopentene based enzyme inhibitors to 
reversibly control the activity of the metabolic branch-point enzyme PriA from Myco-
bacterium tuberculosis (mtPriA) by light. The enzyme’s natural rotational symmetry 
encouraged us to design two-pronged DTEs with terminal phosphate or phosphonate 
functional groups. Switching from the flexible, ring-open to the rigid, ring-closed isomer 
reduces inhibition activity by one order of magnitude, whereby mtPriA’s performance can 
even be remote-controlled by light during catalysis. Molecular Dynamics simulations 
support our experiments showing that the open form is energetically more favorable while 
bound in the active site. Thus the concept of utilizing the enzyme structure for the inhibitor 
design has been proven.  
In chapter 2 the development of photochromic dithienylcyclopentenes as cell signal 
inhibitors for the extracellular-regulated kinase (ERK) pathway is reported. Through 
Molecular Docking we identified promising DTE based ERK inhibitors, which were 
subsequently synthesized and photochemically evaluated. The mediocre thermal stability of 
their ring-closed photoisomers requires that the test solutions are irradiated directly before 
use. Incubation of cells with the title compounds caused significant inhibition by the ring-
open isomers, whereas the ring-closed forms’ activity seems reduced and cytotoxicity was 
observed. Further experiments with isolated ERK could not sufficiently substantiate these 
results though. This already gives a hint on the complexity of this topic as any other tier of 
the entire signal cascade might be affected. Nevertheless, interesting trends were found and 
new compounds could be identified, which allow for the light-dependent regulation of the 
ERK signal. 
Aiming for better water-solubility, increased hydrophilicity and easier derivatization, 
dithienylmaleimide based amino acids were synthesized and incorporated in peptides, as 
described in chapter 3. We combined independently prepared N- and C-terminal thienyl 
components by Perkin condensation to form the maleimide core. Subsequent derivatization 
of the photoswitchable amino acid is easily achieved by standard solid phase peptide 
coupling. The resulting compounds show excellent photochromic performance in polar 
solvents and are thus suitable candidates for biological applications. 
Zusammenfassung 
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Moreover, novel photochromic dithienyl maleic hydrazides are introduced in chapter 4. 
The reaction of dithienylmaleimides with hydrazine generates DTEs bearing maleic 
hydrazide as ethene unit. Initial NMR measurements indicate that it might occur 
predominantly as the monolactim tautomer. Concurrently, we observed photoswitchable 
solvatochromism of the obtained compound, but its repeated application is restricted by 
rapid photodegradation. Further investigations are necessary to thoroughly characterize the 
compounds and their behavior.  These interesting pioneering observations could contribute 
to establish a new generation of DTE photoswitches. 
In conclusion, this thesis presents new concepts for the biological application of 
functionalized photochromic dithienylethenes, which act as light-dependent switches for 
enzyme activity and peptides. The implications of this work are especially relevant for the 
development of novel molecular tools to remote-control cellular processes by light. 
 
Zusammenfassung 
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2 ZUSAMMENFASSUNG 
Diese Arbeit befasst sich mit der Gestaltung, der Synthese und der Untersuchung von neuen 
funktionalisierten photochromen Dithienylethenen (DTEs) für biologische Anwendungen. 
Kapitel 1 handelt von der Entwicklung von Dithienylcyclopenten basierten Enzyminhibitoren, 
die die Aktivität des metabolischen Schlüsselenzyms PriA aus Mycobacterium tuberculosis 
(mtPriA) reversibel durch Licht kontrollieren können. Die natürliche Rotationssymmetrie des 
Enzyms hat uns dazu bewogen, symmetrische Inhibitoren mit terminalen Phosphat- oder 
Phosphonat-Ankern zu entwerfen. Durch das Schalten vom flexiblen, offenen Isomer zur starren, 
geschlossenen Form verringert sich die Inhibitionsaktivität um eine Größenordnung, wobei die 
Enzymsteuerung durch Licht auch während der Katalyse funktioniert. Moleküldynamik-
Simulationen stützen die experimentellen Daten und zeigen, dass die Bindung der offenen Form 
im aktiven Zentrum energetisch bevorzugt ist. Damit wurde bewiesen, dass man abgeleitet von 
der Enzymstruktur Inhibitoren konstruieren kann.  
In Kapitel 2 wird die Anwendung photochromer Dithienylcyclopentene als Zellsignalinhibitoren 
für die Kaskade der extrazellulär regulierten Kinase (ERK) berichtet. Mittels molekularen 
Dockings wurden potentielle, vom DTE-Gerüst abgeleitete, ERK-Inhibitorstrukturen bestimmt, 
welche anschließend synthetisiert und photochemisch untersucht wurden. Die mittelmäßige 
thermische Stabilität der geschlossenen Photoisomere erfordert, dass die Proben direkt vor 
ihrem Einsatz belichtet werden. Bei der Inkubation von Zellen mit den Zielsubstanzen können 
deren offene Isomere das ERK-Signal hemmen, wohingegen die Wirkung der geschlossenen 
Formen geringer erscheint und Zellschädigung festgestellt wurde. Weitere Experimente mit 
isolierter ERK konnten diese Ergebnisse jedoch nicht ausreichend untermauern und deuten auf 
die Komplexität dieser Thematik hin, da jede weitere Stelle der gesamten Signalkaskade 
betroffen sein könnte. Dennoch wurden interessante Tendenzen entdeckt und neue Substanzen 
gefunden, die das ERK-Signal abhängig von der Beleuchtung regulieren können. 
Um die Wasserlöslichkeit zu verbessern, die Hydrophilie zu erhöhen und eine leichtere 
Derivatisierung zu erreichen, wurden Dithienylmaleimid basierte Aminosäuren synthetisiert 
und in Peptide eingebaut, was in Kapitel 3 beschrieben ist. Dabei verknüpften wir die separat 
hergestellten N- und C-terminalen Thienylkomponenten durch eine Perkin-Kondensation, wobei 
der Maleimidkern entstand. Eine anschließende Derivatisierung der photoschaltbaren 
Aminosäure kann durch gewöhnliche Festphasenpeptidsynthese per Standardprotokoll 
erfolgen. Die hergestellten Substanzen zeigen hervorragende photochrome Eigenschaften in 
polaren Lösungsmitteln und eignen sich daher für biologische Anwendungen. 
Zusammenfassung 
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Darüber hinaus werden neue photochrome Dithienyl-Maleinsäurehydrazide in Kapitel 4 
vorgestellt. Die Reaktion von Dithienylmaleimiden mit Hydrazin erzeugt DTEs, die mit einem 
Maleinsäurehydrazid als Etheneinheit ausgestattet sind. Erste NMR-Messungen deuten darauf 
hin, dass es vermutlich als Monolactimtautomer vorliegt. Gleichzeitig beobachteten wir eine 
photoschaltbare Solvatochromie der hergestellten Substanz, jedoch ist eine wiederholte 
Anwendung durch den raschen Zerfall bei Beleuchtung eingeschränkt. Es sind weitere 
Untersuchungen nötig um eine fundierte Charakterisierung vorzunehmen. Diese interessanten 
wegbereitenden Beobachtungen können dazu beitragen eine neue Generation von DTE-
Photoschaltern zu entwickeln. 
Zusammenfassend zeigt diese Arbeit neue Konzepte zur biologischen Anwendung von 
funktionalisierten photochromen Dithienylethenen auf, welche als lichtabhängige Schalter für 
Enzymaktivität und Peptide agieren. Die gewonnenen Erkenntnisse besitzen besondere 
Relevanz im Hinblick auf die Entwicklung von neuartigen molekularen Hilfsmitteln um zelluläre 
Abläufe durch Licht zu kontrollieren. 
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CHAPTER 1 
 
 
3 EXPLOITING PROTEIN SYMMETRY TO DESIGN LIGHT-
CONTROLLABLE ENZYME INHIBITORS* 
 
 
 
 
 
                                                             
* This chapter was published as: B. Reisinger, N. Kuzmanovic, P. Löffler, R. Merkl, B. König and 
R. Sterner, Angew. Chem. 2014, 126, 606-609; Angew. Chem. Int. Ed. 2014, 53, 595-598. BR and NK 
contributed equally to this work. Design, calculations, synthesis, characterization and photophysical 
investigations of new compounds by NK. Protein cloning, expression, purification, steady-state 
enzyme kinetics and manuscript by BR (group of Prof. Dr. R. Sterner, University of Regensburg). 
Molecular Modeling by PL (group of Prof. Dr. R. Merkl, University of Regensburg). BK and RS 
supervised the project and are the corresponding authors. 
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3.1 Introduction 
The artificial control of biological processes by light is a rapidly emerging area of protein 
design.[1] Three basic strategies for the light-regulation of biomolecules have been reported: 
Besides caging of key positions with photolabile protecting groups[2] and reprogramming of 
naturally occurring photoreceptors,[3-5] designed molecules that can be reversibly switched 
by light (photoswitches) have been used to direct protein or cellular function.[6] Recently, 
substantial progress has been made in the regulation of neuronal activity by designing light-
inducible ligands for ion channels and receptors.[7-8] As the molecular recognition of specific 
ligand parts leads to a nonlinear signal response in neural systems, even small changes in 
the binding efficacy upon light irradiation significantly influence the cellular output.[9] 
However, when aiming to reversibly control enzymatic activities, switching of a 
photoresponsive group must substantially affect the enzyme’s active site. Covalent 
incorporation of a molecular photoswitch near the catalytic center is able to fulfill this 
task.[6, 10] The required coupling step between protein and photoswitch can be circumvented 
by designing a light-controlled inhibitor.[6, 11-13] 
 
Figure 1. Reversible light-dependent control of mtPriA activity.  
We aimed to design a light-controllable inhibitor for phosphoribosyl-isomerase A from 
Mycobacterium tuberculosis (mtPriA, Figure 1). mtPriA is a branch-point enzyme in amino 
acid biosynthesis as it catalyzes two chemically equivalent sugar isomerization reactions in 
tryptophan and histidine biosynthesis.[14] In the latter, the aminoaldose N′-[(5′-
phosphoribosyl)-formimino]-5-aminoimidazole-4-carboxamide ribonucleotide (ProFAR) is 
converted to the corresponding aminoketose N´-[(5´-phosphoribulosyl)-formimino]-5-
aminoimidazole-4-carboxamide-ribonucleotide (PRFAR) (Figure 2a). Since humans can 
neither synthesize histidine nor tryptophan, mtPriA is a potential target for anti-
tuberculosis drugs.[15-16] Structurally, mtPriA belongs to the class of (βα)8-barrels, which is a 
frequently encountered and highly versatile fold among enzymes.[17-18] mtPriA exhibits a 
clear twofold symmetry (Figure 2b),[19-20] which indicates its evolution from a (βα)4-half-
barrel precursor.[21] Consequently, two phosphate binding sites are found opposite each 
other to fix the substrate ProFAR and the product PRFAR (Figure 2b). We thus reasoned that 
Chapter 1 
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a C2-symmetric photoswitch with terminal phosphate-anchors would be an excellent 
foundation for building a light-controllable inhibitor of mtPriA. 
 
Figure 2. Reaction and structure of mtPriA. a) mtPriA catalyzes the conversion of ProFAR to PRFAR 
within histidine biosynthesis. b) Ribbon diagram of the (βα)8-barrel structure of mtPriA with bound 
product PRFAR (PDB ID 3ZS4[19]). The view is along the two-fold symmetry axis of the protein. PRFAR is 
anchored by two opposite phosphate binding sites, which are enlarged in the insets. Formed 
hydrogen bonds are indicated by dashed lines (structure is slightly rotated for clarity in either case).  
Two types of organic photochromic systems possess the desired twofold rotational 
symmetry: stilbene[22] or azobenzene switches[23] and the diarylethene scaffold.[24] Although 
azobenzene derivatives have been widely used in biological systems, they suffer from 
incomplete photoconversion and thermal reversibility.[1] In contrast, photoresponsive 
compounds based on 1,2-dithienylethene (DTE) generally feature switching rates of over 
90% conversion with both photoisomers being thermally stable.[12, 24] Hence, we opted for 
DTE as core and provided it with different phosphate and phosphonate anchors (Scheme 1). 
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3.2 Results and Discussion 
3.2.1 Synthesis 
Starting with the bischlorodithienylethene 1, Suzuki coupling yielded either the aromatic 
hydroxides 2-4 or the aromatic bromides 8-9. The former were subsequently converted to 
ortho-, meta- and para-phosphates 5-7, while the latter were used to synthesize the 
phosphonic acid esters 10-11, which were finally hydrolyzed to afford meta- and para-
phosphonates 12-13. 
 
Scheme 1. Synthesis of DTE-phosphates and DTE-phosphonates. 
 
  
Chapter 1 
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3.2.2 Photochromism 
The DTE molecular structure can reversibly be toggled between a ring-open and ring-closed 
photoisomer (Scheme 2), which significantly alters its overall conformational flexibility.[12] 
Energy minimizations of the open and closed forms of all potential inhibitors confirmed for 
the phosphorous atoms distances between 15.8 and 19.6 Å (Scheme 2), which is in good 
accordance with the 16.9 Å observed for the corresponding atoms in the mtPriA structure 
with co-crystallized PRFAR (PDB ID 3ZS4[19]) (see Experimental Material and Methods for 
details). Only the open and closed isomers of ortho-phosphate 5 exhibit rather short P-P 
distances of 12.3 Å and 11.3 Å, respectively, in their energetically most favorable 
geometries; in addition, less populated, more extended conformers can be observed. 
 
Scheme 2. Photochemical switching and corresponding calculated P-P distances in DTE-
phosphates and DTE-phosphonates.  
When ring-open forms of compounds 5-7, 12 and 13 are irradiated with 312 nm light, the 
absorption band at 280 nm immediately decreases. Simultaneously, new absorption maxima 
at 350 nm and 525 nm are formed turning the initially colorless solutions pink (see Figure 
5). In each case, the spectral changes are completed after 30 s of irradiation and the 
corresponding photostationary states contain between 93% and 97% of the closed isomers, 
as judged by HPLC analyses (see Figure 6). The open forms can be recovered by irradiation 
with visible light (> 420 nm) and all switches are robust over several ring-closing/ring-
opening cycles (see Figure 7). 
Exploiting Protein Symmetry to Design Light-Controllable Enzyme Inhibitors 
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3.2.3 Biological Test Results 
The mtPriA activity can be monitored spectrophotometrically at 300 nm in a coupled 
enzyme assay (Scheme 3).[25] As all synthesized compounds were stable under assay 
conditions, their inhibitory effect could be investigated in steady-state enzyme kinetics. For 
this purpose, substrate saturation curves were measured in presence of different 
concentrations of compounds 5-7, 12 and 13 in their open and closed forms (curves are 
shown for compound 6 in Figure 8). Indeed, all investigated DTE-phosphates and DTE-
phosphonates have the ability to inhibit the mtPriA reaction in both isomeric forms, thus 
proving the viability of the design concept. As expected for competitive inhibition, the 
turnover numbers kcat were identical in presence and absence of inhibitor (see experimental 
section, Table 2). The observed increase of the Michaelis constants caused by the inhibitors 
(Table 2) was used to calculate the inhibition constants Ki (Formula 1), which are given in 
Table 1. 
Table 1. Inhibition constants Ki of compounds 5-7, 12 and 13 in their ring-open and ring-closed forms. 
Inhibitor Ki / µM[a] 
ring-open     ring-closed 
5 8.1 ± 2.1 7.0 ± 1.2 
6 
7 
12 
13 
0.55 ± 0.12 
3.5 ± 0.3 
1.6 ± 0.1 
6.8 ± 0.6 
4.4 ± 0.3 
3.7 ± 0.4 
4.9 ± 0.3 
22.7 ± 4.7 
[a] The values of Ki were obtained from the data shown in Table 2 using Formula 1. 
The determined inhibition constants are in the low micromolar range (Table 1) and 
therefore comparable or even better than the enzyme’s KM value for the natural substrate 
ProFAR (KMProFAR = 8.6 µM; see Table 2). In agreement with the well-suited distance of its 
phosphorous atoms (Scheme 2), the open isomer of phosphate 6 exhibits the highest 
binding affinity (Ki = 0.55 µM). However, when switched to its rigid, closed form, the 
inhibition activity is lowered by roughly one order of magnitude (Ki = 4.4 µM). A similar 
trend is observed for the respective phosphonate 12, whose binding affinity in the open 
form (Ki = 1.6 µM) is decreased about 3-fold upon ring-closure (Ki = 4.9 µM). In contrast, the 
inhibitory effects of phosphates 5 and 7 are nearly identical in their ring-open and ring-
closed forms (Table 1). Interestingly, the introduction of a phosphonate moiety in para-
position (compound 13) causes a 3-fold difference in the inhibition activity of the open (Ki = 
6.8 µM) and closed photoisomer (Ki = 22.7 µM). The removal of the oxygen bridge between 
Chapter 1 
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the terminal anchor and the switchable core further reduces the overall flexibility, which 
seems to predominantly affect the already rigid, closed isomer.  
The performance of mtPriA can also be remote-controlled by light during catalysis. Starting 
up with compound 6 in its strongly inhibiting, open form, the reaction velocity is enhanced 
about 3-fold, when switching to the less active, ring-closed isomer (Figure 3).  
 
Figure 3. Change in mtPriA activity upon ring-closure of compound 6. The turnover of 5 µM ProFAR 
was followed photometrically at 300 nm in the presence of 4 µM 6 in its open form under typical 
assay conditions (25 °C, 50 mM Tris/acetate pH 8.5, 100 mM ammonium acetate, 0.18 µM HisF and 
0.15 µM mtPriA). After having reached its maximal velocity, the reaction mixture was either left in 
the photometer (grey) or removed to irradiate it with 312 nm light for 10 s (black). A reference 
solution without enzymes was used to correct the baseline shift resulting from different absorption 
values of the open and closed isomer at 300 nm. 
 
3.2.4 Molecular Modeling 
As pointed out before, the mechanistic principle, which induces the different binding 
affinities of the photoisomers, is based on a change in conformational flexibility.[12] Due to 
free rotation around the C-C bonds joining the thiophene heterocycles with the central 
cyclopentene ring and the terminal phenyl groups, DTE-phosphate 6 is able to adopt various 
geometries in its ring-open form. On the other hand, the closed isomer is completely 
conjugated and thus far more restricted in its motility. In order to get insights into the 
binding modes of the inhibitors, Molecular Dynamics (MD) simulations of the open and 
closed isomer of compound 6 bound to mtPriA were performed. Although both forms are 
clearly fixed at the phosphate binding sites (Figure 4a and 4c), obvious differences can be 
observed in their structural cores. While the open isomer converges to similar, 
Exploiting Protein Symmetry to Design Light-Controllable Enzyme Inhibitors 
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C2-symmetric conformers in three independent calculations (Figure 4b), more diverse 
binding modes are found for the ring-closed isomer (Figure 4d). Here, one terminal phenyl 
ring is twisted and adopts various geometries to facilitate proper coordination of the 
terminal phosphate group. The measured difference in inhibition activity is also reflected in 
the binding energies determined during the simulations, which consistently show that 
interaction with the open form is energetically more favorable (see Table 3). Taken 
together, the higher flexibility of the open isomer allows for better adaptation to the 
enzyme’s active site and apparently overcompensates the loss in entropy upon binding. 
 
Figure 4. MD simulations of mtPriA and bound meta-phosphate 6. For each isomer, three 
independent calculations were performed and representative enzyme structures for the open (a) 
and closed (c) form are shown. A superposition of the energetically most favorable conformer of 
each simulation is depicted in the open conformation (b) and the closed conformation (d). 
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3.3 Conclusion 
In summary, we have demonstrated that natural protein symmetry can be advantageously 
utilized to design light-controllable enzyme inhibitors. The two-pronged DTE switches can 
reversibly be toggled between a high- and low-affinity form, where both photoisomers are 
nearly quantitatively formed and thermally stable. Hence, the enzyme’s performance can 
alternately be enhanced and reduced by irradiation with UV and visible light, respectively. 
The viability of a dual-anchored DTE inhibitor has been shown before[12] and the design 
concept can in principle be transferred to functionally quite different enzyme systems. 
Phosphate is a frequently encountered element of metabolic substrates, and various other 
(βα)8-barrel enzymes such as pyridoxine 5’-phosphate synthase[26] or aldolases[27-28] possess 
two phosphate binding sites. For these enzymes, inhibitors may be designed with a similar 
approach, which would allow for an independent photocontrol of several metabolic 
processes in a spatiotemporal fashion. 
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3.4 Supporting Information 
3.4.1 Synthesis and Characterization of New Compounds 
General. Commercial reagents and starting materials were purchased from Acros Organics, 
Alpha-Aesar or Sigma Aldrich and used without further purification. Solvents were used in 
p.a. quality and dried according to common procedures, if necessary. Flash column 
chromatography was performed on a Biotage Isolera One automated flash purification 
system with UV/Vis detector using Sigma Aldrich MN silica gel 60 M (40-63 µm, 230-400 
grain diameter) for normal phase or pre-packed Biotage SNAP cartridges (KP-C18-HS) for 
reversed phase chromatography. Reaction monitoring via TLC was performed on alumina 
plates coated with silica gel (Merck silica gel 60 F254, 0.2 mm). NMR spectra were recorded 
on a Bruker Avance 400 (1H 400.13 MHz, 13C 100.61 MHz, 31P 161.96 MHz, T = 300 K) 
instrument. The spectra are referenced against the NMR-solvent, chemical shifts δ are 
reported in ppm and coupling constants J are given in Hz. Resonance multiplicity is 
abbreviated as: s (singlet), d (doublet), t (triplet), m (multiplet) and b (broad). Carbon NMR 
signals are reported using DEPT 135 spectra with (+) for primary/tertiary, (−) for 
secondary and (q) for quaternary carbons. Mass spectra were recorded on Finnigan MAT95 
(EI-MS), Agilent Q-TOF 6540 UHD (ESI-MS, APCI-MS), Finnigan MAT SSQ 710 A (EI-MS, CI-
MS) or ThermoQuest Finnigan TSQ 7000 (ES-MS, APCI-MS) spectrometer. UV/Vis 
absorption spectroscopy was performed using a Varian Cary BIO 50 UV/Vis/NIR 
spectrometer. 
Photochemistry. Standard hand-held lamps (Herolab, 312 nm, 6 W) were used for 
visualizing TLC plates and to carry out the ring-closure reactions at 312 nm. The ring-
opening reactions were performed with the light of a 200 W tungsten light bulb which was 
passed through a 420 nm cut-off filter to eliminate higher energy light. The power of the 
light is given based on the specifications supplied by the company when the lamps were 
purchased. A light detector was not used to measure the intensity during the irradiation 
experiments. 
General procedure A for Suzuki coupling. 1,2-Bis(5-chloro-2-methylthiophen-3-
yl)cyclopent-1-ene 1[29] (1.0 eq.) was dissolved in dry THF under nitrogen atmosphere. After 
cooling to -78 °C, n-butyl lithium (2.2 eq.) was added dropwise via syringe and the resulting 
purple solution was stirred in the cold for 45 min. The reaction mixture was treated with 
trimethyl borate (4.0 eq.) and the yellow solution was stirred at -78 °C for 30 min. 
Subsequently, the cold bath was removed and the reaction was stirred at r.t. for further 
60 min to form the boronic ester intermediate. After quenching with aqueous sodium 
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carbonate (2 M) the two phase system was degassed for 15 min by nitrogen purge. Then the 
appropriate aryl bromide (2.2 or 4.0 eq.) and Pd(PPh3)2Cl2 (10 mol%) were added and the 
reaction mixture was heated to reflux overnight. After cooling to r.t., it was diluted with 
EtOAc and water and the phases were separated. The aqueous phase was extracted with 
EtOAc twice, the combined organic phases were dried over sodium sulfate and the solvents 
removed under reduced pressure. Purification of the crude product was performed by 
automated flash column chromatography. 
General procedure B for phosphate ester formation. A crimp top vial was equipped with 
the desired bisphenol DTE (1.0 eq.) and a stirring bar and capped. It was set under nitrogen 
atmosphere and pyridine (20 eq.) in dry CH2Cl2 (1 mL) was added by syringe. After cooling 
to 0 °C a solution of phosphorous oxychloride (10 eq.) in dry THF (1 mL) was added 
dropwise via syringe over 5 min. The purple reaction mixture was stirred for 2 h at r.t. 
under nitrogen atmosphere and subsequently quenched with acetone/water (1:1, 2 mL). 
Volatiles were removed in vacuo and the crude product was purified by automated reversed 
phase flash column chromatography. 
 
Synthesis of 2,2'-(4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl)) 
diphenol (2). Compound 2 was prepared from 1,2-bis(5-chloro-2-methylthiophen-3-
yl)cyclopent-1-ene 1 (1.50 g, 4.55 mmol), n-butyl lithium (1.3 M in hexane, 7.68 mL, 
10.0 mmol), trimethyl borate (2.03 mL, 18.2 mmol), 2-bromophenol (1.16 mL, 10.0 mmol) 
and Pd(PPh3)2Cl2 (320 mg, 0.46 mmol) following the general procedure A for Suzuki 
coupling with 50 mL dry THF and 20 mL aq. Na2CO3 (2 M). Automated flash column 
chromatography (PE/EtOAc, 15-25% EtOAc) and subsequent reversed phase automated 
flash column chromatography (MeOH/water with 0.05% TFA, 3-100% MeOH) afforded 
223 mg (0.50 mmol, 11%) of 2 as purple oil. 1H-NMR: δH(400 MHz, CDCl3): 2.10 (2H, dt, 
J = 7.4, 7.5 Hz, cyclopentene-CH2), 2.16 (6H, s, 2 CH3), 2.84 (4H, t, J = 7.4 Hz, 2 cyclopentene-
CH2), 6.85 (2H, s, 2 thiophene-H), 6.89 − 6.97 (4H, m, 4 phenyl-H), 7.15 − 7.22 (2H, m, 
phenyl-H), 7.30 (2H, dd, J = 7.6, 1.6 Hz, phenyl-H); 13C-NMR: δC(101 MHz, CDCl3): 14.1 (+), 
23.2 (−), 37.8 (−), 116.3 (+), 120.8 (+), 121.1 (q), 127.6 (+), 129.2 (+), 129.8 (+), 134.5 (q), 
135.4 (q), 135.6 (q), 136.6 (q), 152.4 (q); ESI-MS: m/z (%): 443.1 (100) [M-H]-; calcd. for 
C27H24O2S2 443.1145; found 443.1147. 
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Synthesis of 3,3'-(4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl)) 
diphenol (3). Compound 3 was prepared from 1,2-bis(5-chloro-2-methylthiophen-3-
yl)cyclopent-1-ene 1 (1.84 g, 5.59 mmol), n-butyl lithium (1.6 M in hexane, 7.68 mL, 
12.3 mmol), trimethyl borate (2.49 mL, 22.4 mmol), 3-bromophenol (2.13 g, 12.3 mmol) and 
Pd(PPh3)2Cl2 (393 mg, 0.56 mmol) following the general procedure A for Suzuki coupling 
with 100 mL dry THF and 20 mL aq. Na2CO3 (2 M). Automated flash column 
chromatography (PE/EtOAc, 15-30% EtOAc) and subsequent reversed phase automated 
flash column chromatography (MeOH/water with 0.05% TFA, 30-100% MeOH) afforded 
1.04 g (2.35 mmol, 42%) of 3 as red oil. 1H-NMR: δH(400 MHz, CDCl3): 2.00 (6H, s, 2 CH3), 
2.08 (2H, dt, J = 7.4 Hz, cyclopentene-CH2), 2.83 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 3.51 
(2H, bs, 2 phenyl-OH), 6.71 (2H, dd, J = 1.9 Hz, 8.0 Hz, 2 phenyl-H), 6.95 − 6.99 (2H, m, 
2 phenyl-H), 7.00 (2H, s, 2 thiophene-H), 7.07 (2H, J = 7.9 Hz, 2 phenyl-H), 7.19 (2H, t, J  = 
7.9 Hz, 2 phenyl-H); 13C-NMR: δC(101 MHz, CDCl3): 14.4 (+), 23.0 (−), 38.4 (−), 112.2 (+), 
114.1 (+), 117.9 (+), 124.4 (+), 130.1 (+), 134.7 (q), 134.8 (q), 136.1 (q), 136.7 (q), 139.2 (q), 
156.0 (q); EI-MS: m/z (%) 444.1 (100) [M]+, 429.0 (35) [M-CH3]+; calcd. for C27H24O2S2 
443.1145; found 443.1156. 
 
Synthesis of 4,4'-(4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl)) 
diphenol (4). Compound 4 was prepared from 1,2-bis(5-chloro-2-methylthiophen-3-
yl)cyclopent-1-ene 1 (209 mg, 0.64 mmol), n-butyl lithium (1.6 M in hexane, 0.88 mL, 
1.41 mmol), trimethyl borate (0.29 mL, 2.56 mmol), 4-bromophenol (439 mg, 2.54 mmol) 
and Pd(PPh3)2Cl2 (42 mg, 0.06 mmol) following the general procedure A for Suzuki coupling 
with 50 mL dry THF and 10 mL aq. Na2CO3 (2 M). Automated flash column chromatography 
(PE/EtOAc, 15-25% EtOAc), subsequent reversed phase automated flash column 
chromatography (MeOH/water with 0.05% TFA, 30-100% MeOH) and lyophilization 
afforded 127 mg (0.29 mmol, 45%) of 4 as red oil. 1H-NMR: δH(400 MHz, CDCl3): 1.98 (6H, 
s, 2 CH3), 2.10 (2H, p, J = 7.7 Hz, cyclopentene-CH2), 2.83 (4H, t, J = 7.5 Hz, 
2 cyclopentene-CH2), 4.88 (2H, bs, 2 phenyl-OH), 6.80 (4H, d, J = 8.7 Hz, 4 phenyl-H), 6.90 
(2H, s, 2 thiophene-H), 7.37 (4H, d, J = 8.7 Hz, 4 phenyl-H); 13C-NMR: δC(101 MHz, CDCl3): 
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14.4 (+), 23.0 (−), 38.5 (−), 115.7 (+), 123.1 (+), 126.8 (+), 127.7 (q), 133.5 (q), 134.6 (q), 
136.6 (q), 139.4 (q), 154.8 (q); EI-MS: m/z (%) 444.0 (100) [M]+, 429.0 (35) [M-CH3]+; calcd. 
for C27H24O2S2 443.1145; found 443.1148. 
 
Synthesis of (4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl))bis(2,1-
phenylene) bis(phosphate) (5). Compound 5 was prepared from 2 (65 mg, 0.15 mmol), 
pyridine (0.24 mL, 2.92 mmol) and phosphorous oxychloride (0.13 mL, 1.46 mmol) 
following the general procedure B for phosphate ester formation. Automated reversed 
phase flash column chromatography (MeOH/water with 0.5% NEt3, 20-100% MeOH) and 
subsequent lyophilization afforded 66 mg (0.09 mmol, 58%) of 5 as purple foam. 1H-NMR: 
δH(400 MHz, MeOD): 1.21 (18H, t, J = 7.3 Hz, 2 H+N(CH2CH3)3), 1.99 (6H, s, 2 thiophene-
CH3), 2.04 − 2.13 (2H, m, cyclopentene-CH2), 2.87 (4H, t, J = 7.5 Hz, 2 cyclopentene-CH2), 3.03 
(12H, q, J = 7.3 Hz, 2 H+N(CH2CH3)3), 6.99 (2H, t, J = 7.6 Hz, 2 phenyl-H), 7.10 − 7.18 (2H, m, 
2 phenyl-H), 7.40 (2H, s, thiophene-H), 7.51 (2H, d, J = 7.8 Hz, 2 phenyl-H), 7.63 (2H, d, J = 
8.3 Hz, 2 phenyl-H); 13C-NMR: δC(101 MHz, MeOD): 9.1 (+), 14.4 (+), 24.0 (−), 39.6 (−), 
47.5 (−), 121.4 (+), 123.8 (+), 126.6 (q), 128.2 (+), 128.4 (+), 128.7 (+), 135.8 (q), 136.1 (q), 
136.5 (q), 137.4 (q), 150.8 (q); 31P-NMR: δP(162 MHz, MeOD): -3.40 (s); ESI-MS: m/z (%) 
806.0 (100) [(M4-+3H)+2(N(Et)3)]-, 603.0 (44) [M4-+3H]-; calcd. for C27H25O8P2S2 603.0472; 
found 603.0477. 
 
Synthesis of (4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl))bis(3,1-
phenylene) bis(phosphate) (6). Compound 6 was prepared from 3 (26 mg, 0.06 mmol), 
pyridine (100 µL, 1.18 mmol) and phosphorous oxychloride (50 µL, 0.56 mmol) following 
the general procedure B for phosphate ester formation. Automated reversed phase flash 
column chromatography (MeOH/water with 0.5% NEt3, 20-100% MeOH) and subsequent 
lyophilization afforded 33 mg (0.03 mmol, 56%) of 6 as purple foam. 1H-NMR: δH(400 MHz, 
MeOD): 1.21 (36H, t, J = 7.3 Hz, 4 H+N(CH2CH3)3), 1.96 (6H, s, 2 thiophene-CH3), 2.11 (2H, dt, 
J = 7.5, 7.6 Hz, cyclopentene-CH2), 2.86 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 2.97 (24H, q, 
J = 7.3 Hz, 4 H+N(CH2CH3)3), 7.11 − 7.13 (4H, m, 4 phenyl-H), 7.15 (2H, s, 2 thiophene-H), 
7.17 − 7.23 (2H, m, 2 phenyl-H), 7.50 (2H, s, 2 phenyl-H); 13C-NMR: δC(101 MHz, MeOD): 
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9.5 (+), 14.5 (+), 24.1 (−), 39.5 (−), 47.1 (−), 118.1 (+), 120.0 (+), 120.3 (+), 125.3 (+), 
130.5 (+), 135.3 (q), 136.1 (q), 136.7 (q), 138.2 (q), 141.1 (q), 156.4 (q); 31P-NMR: 
δP(162 MHz, MeOD): -0.78 (s); ESI-MS: m/z (%) 806.0 (100) [(M4-+3H)+2(N(Et)3)]-, 
603.0 (21) [M4-+3H]-; calcd. for C27H25O8P2S2 603.0472; found 603.0478. 
 
Synthesis of (4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl))bis(4,1-
phenylene) bis(phosphate) (7). Compound 7 was prepared from 4 (50 mg, 0.11 mmol), 
pyridine (191 µL, 2.36 mmol) and phosphorous oxychloride (103 µL, 1.12 mmol) following 
the general procedure B for phosphate ester formation. Automated reversed phase flash 
column chromatography (MeOH/water with 0.5% NEt3, 20-100% MeOH) and subsequent 
lyophilization afforded 73 mg (0.07 mmol, 64%) of 7 as purple oil.  1H-NMR: δH(400 MHz, 
MeOD): 1.26 (36H, t, J = 7.3 Hz, 4 H+N(CH2CH3)3), 1.99 (6H, s, 2 thiophene-CH3), 2.08 (2H, dt, 
J = 7.5, 7.6 Hz, cyclopentene-CH2), 2.84 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 3.09 (24H, q, 
J = 7.3 Hz, 4 H+N(CH2CH3)3), 6.97 (2H, s, 2 thiophene-H), 7.20 (4H, d, J = 8.7 Hz, 4 phenyl-H), 
7.40 (4H, d, J = 8.6 Hz, 4 phenyl-H); 13C-NMR: δC(101 MHz, MeOD): 9.2 (+), 14.5 (+), 
24.1 (−), 39.3 (−), 47.4 (−), 121.8 (+), 124.6 (+), 127.1 (+), 130.6 (q), 134.8 (q), 136.2 (q), 
138.1 (q), 140.9 (q), 154.5 (q); 31P-NMR: δP(162 MHz, MeOD): -2.26 (s); ESI-MS: m/z (%) 
806.0 (100) [(M4-+3H)+2(N(Et)3)]-, 603.0 (15) [M4-+3H]-; calcd. for C27H25O8P2S2 603.0472; 
found 603.0465. 
 
Synthesis of tetraethyl((4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-
diyl))bis(3,1-phenylene)) bis(phosphonate) (10). A crimp top vial was loaded with 
compound 8[30] (277 mg, 0.49 mmol), palladium acetate (11 mg, 0.05 mmol), 
triphenylphosphine (39 mg, 0.15 mmol) and a stirring bar and capped. It was set under 
nitrogen atmosphere at which point diethyl phosphite (0.15 mL, 1.18 mmol), triethylamine 
(0.20 mL, 1.47 mmol) and ethanol (4 mL) were added via syringes and the purple solution 
was refluxed for 48 h. After cooling to r.t. the reaction mixture was diluted with ethanol 
(5 mL), transferred to a round bottom flask and the volatiles were removed at the rotary 
evaporator. The brown residue was purified by automated flash column chromatography 
(PE/EtOAc, 40-95% EtOAc) yielding 10 (128 mg, 0.19 mmol, 39%) as purple oil. 1H-NMR: 
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δH(400 MHz, CDCl3): 1.29 (12H, t, J = 7.1 Hz, 2 P(O)(OCH2CH3)2), 1.96 (6H, s, 2 thiophene-
CH3), 1.99 − 2.13 (2H, m, cyclopentene-CH2), 2.82 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 
3.91 − 4.24 (8H, m, 2 P(O)(OCH2CH3)2), 7.10 (2H, s, 2 thiophene-H), 7.39 (4H, td, J = 7.7, 
4.4 Hz, 2 phenyl-H), 7.54 − 7.71 (4H, m, 4 phenyl-H), 7.93 (2H, dt, J = 14.1, 1.4 Hz, 
2 phenyl-H); 13C-NMR: δC(101 MHz, CDCl3): 14.5 (+), 16.3 (+), 23.0 (−), 38.6 (−), 62.2 (−), 
124.8 (+), 128.2 (+), 128.3 (q), 129.0 (+), 129.1 (+), 130.0 (+), 134.7 (q), 134.9 (q), 135.4 (q), 
136.9 (q), 138.4 (q); 31P-NMR: δC(162 MHz, CDCl3): 19.0 (s); ESI-MS: m/z (%) 685.2 (100) 
[M+H]+, 1391.4 (65) [2M+Na]+; calcd. for C35H42O6P2S2 685.1971; found 685.1976. 
 
Synthesis of tetraethyl ((4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-
diyl))bis(4,1-phenylene)) bis(phosphonate) (11). A crimp top vial was loaded with 
compound 9[31] (248 mg, 0.44 mmol), palladium acetate (10 mg, 0.04 mmol), 
triphenylphosphine (34 mg, 0.14 mmol) and a stirring bar and capped. It was set under 
nitrogen atmosphere at which point diethyl phosphite (0.13 mL, 1.04 mmol), triethylamine 
(0.18 mL, 1.31 mmol) and ethanol (4 mL) were added via syringes and the purple solution 
was refluxed for 48 h. After cooling to r.t. the reaction mixture was diluted with ethanol 
(5 mL), transferred to a round bottom flask and the volatiles were removed at the rotary 
evaporator. The brown residue was purified by automated flash column chromatography 
(PE/EtOAc, 95% EtOAc) yielding 11 (102 mg, 0.15 mmol, 34%) as purple oil. 1H-NMR: 
δH(400 MHz, CDCl3): 1.31 (12H, t, J = 7.1 Hz, 2 P(O)(OCH2CH3)2), 1.99 (6H, s, 2 thiophene-
CH3), 2.02 − 2.14 (2H, m, cyclopentene-CH2), 2.83 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 
3.92 − 4.29 (8H, m, 2 P(O)(OCH2CH3)2), 7.11 (2H, s, 2 thiophene-H), 7.55 (4H, dd, J = 8.3, 
3.7 Hz, 4 phenyl-H), 7.75 (4H, dd, J = 12.9, 8.3 Hz, 4 phenyl-H); 13C-NMR: δC(101 MHz, 
CDCl3): 14.5 (+), 16.3 (+), 16.4 (+), 23.0 (−), 38.5 (−), 62.1 (−), 124.9 (+), 125.1 (+), 125.4 (+), 
127.2 (q), 132.4 (+), 132.5 (+), 134.8 (q), 136.2 (q), 137.0 (q), 138.2 (q), 138.4 (q); 31P-NMR: 
δC(162 MHz, CDCl3): 19.3 (s); ESI-MS: m/z (%) 685.2 (100) [M+H]+, 1391.4 (44) [2M+Na]+; 
calcd. for C35H42O6P2S2 685.1971; found 685.1977. 
 
Synthesis of ((4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl))bis(3,1-
phenylene))diphosphonic acid (12). Compound 10 (118 mg, 0.17 mmol) was dissolved in 
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dry acetonitrile (15 mL) and treated with trimethylsilyl bromide (1.14 mL, 8.62 mmol). The 
reaction mixture was stirred at r.t. overnight. Volatiles were removed at the rotary 
evaporator. After purification by automated reversed phase flash column chromatography 
(MeOH/water with 0.5% NEt3, 3-100% MeOH) and lyophilization compound 12 (114 mg, 
0.15 mmol, 87%) was obtained as dark purple oil. 1H-NMR: δH(400 MHz, MeOD): 1.23 
(18H, t, J = 7.3 Hz, 2 H+N(CH2CH3)3), 1.98 (6H, s, 2 thiophene-CH3), 2.05 − 2.16 (2H, m, 
cyclopentene-CH2), 2.86 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 3.07 (12H, q, J = 7.3 Hz, 
2 H+N(CH2CH3)3), 7.16 (2H, s, thiophene-H), 7.33 (2H, td, J = 7.7, 3.5 Hz, 2 phenyl-H), 
7.44 − 7.59 (2H, m, 2 phenyl-H), 7.67 (2H, dd, J = 12.1, 7.5 Hz, 2 phenyl-H), 8.01 (2H, d, 
J = 13.1 Hz, 2 phenyl-H); 13C-NMR: δC(101 MHz, MeOD): 9.2 (+), 14.6 (+), 24.1 (−), 39.5 (−), 
47.4 (−), 125.4 (+), 127.4 (+), 128.7 (+), 129.5 (+), 130.6 (+), 135.2 (q), 135.7 (q), 136.2 (q), 
138.3 (q), 139.2 (q), 141.0 (q); 31P-NMR: δP(162 MHz, MeOD): 12.5 (s); ESI-MS: m/z (%) 
571.1 (100) [M4-+3H]-; calcd. for C27H25O6P2S2 571.0573; found 571.0570. 
 
Synthesis of ((4,4'-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-4,2-diyl))bis(4,1-
phenylene))diphosphonic acid (13). Compound 11 (82 mg, 0.12 mmol) was dissolved in 
dry acetonitrile (5 mL) and treated with trimethylsilyl bromide (0.79 mL, 6.00 mmol). The 
reaction mixture was stirred at r.t. overnight. Volatiles were removed at the rotary 
evaporator. After purification by automated reversed phase flash column chromatography 
(MeOH/water with 0.5% NEt3, 3-100% MeOH) and lyophilization compound 13 (76 mg, 
0.10 mmol, 82%) was obtained as dark purple oil. 1H-NMR: δH(400 MHz, MeOD): 1.25 
(18H, t, J = 7.3 Hz, 2 H+N(CH2CH3)3), 1.99 (6H, s, 2 thiophene-CH3), 2.09 (2H, dt, J = 7.5, 
7.6 Hz, cyclopentene-CH2), 2.85 (4H, t, J = 7.4 Hz, 2 cyclopentene-CH2), 3.09 (12H, q, J = 
7.3 Hz, 2 H+N(CH2CH3)3), 7.17 (2H, s, thiophene-H), 7.50 (4H, dd, J = 8.4, 2.8 Hz, 4 phenyl-H), 
7.73 (4H, dd, J = 12.1, 8.3 Hz, 4 phenyl-H); 13C-NMR: δC(101 MHz, MeOD): 9.2 (+), 14.7 (+), 
24.1 (−), 39.4 (−), 47.4 (−), 125.4 (+), 125.8 (q), 132.6 (+), 136.2 (q), 136.7 (q), 136.9 (q), 
138.4 (q), 138.5 (q), 140.7 (q); 31P-NMR: δP(162 MHz, MeOD): 12.9 (s); ESI-MS: m/z (%) 
571.1 (100) [M4-+3H]-; calcd. for C27H25O6P2S2 571.0573; found 571.0579. 
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3.4.2 Photochromism of DTE-phosphates and DTE-phosphonates 
Photochemical syntheses of ring-closed isomers. Solutions of compounds 5-7, 12 and 13 
(12.5 µM) in 50 mM Tris/acetate pH 8.5 were irradiated for 30 s with a 312 nm lamp 
yielding pink solutions containing the ring-closed isomers. The changes in the UV/Vis 
absorption spectra are representatively shown for compound 6 in Figure 5. The 
photostationary states contain between 93 and 97% of the ring-closed isomers according to 
HPLC analyses. The respective HPLC chromatograms of compound 6 in its open and closed 
form are depicted in Figure 6. 
 
Figure 5. UV/Vis absorption spectra evolution of compound 6 upon irradiation with 312 nm light. 
Arrows indicate the changes of the absorption maxima of 12.5 µM 6 in 50 mM Tris/acetate pH 8.5 
with irradiation intervals of 2 s from 0 to 30 s, which is illustrated by the color change from blue 
(open isomer) to purple (closed isomer). 
Photochemical cycling studies. In order to test the robustness of the photochromic 
systems, photochemical cycling studies were recorded for all switches (Figure 7). In each 
case, a solution of 12.5 µM inhibitor in 50 mM Tris/acetate pH 8.5 was alternately irradiated 
with 312 nm light for 30 s and with visible light for 15 min over various cycles and the 
absorption change at 525 nm was monitored. 
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Figure 6. Representative HPLC chromatograms for the determination of the photostationary state of 
compound 6 (100 µM in 50 mM Tris/acetate pH 8.5). The UV/Vis signal was detected at 288 nm. The 
chromatograms before (upper) and after (lower) irradiation with 312 nm light for 30 s indicate that 
97% of the open isomer (blue curve) were converted to the closed isomer (red curve). The 
absorption spectra of both forms are shown in the right panel. 
 
Figure 7. Cycle performance of compounds 5-7, 12 and 13. Changes in absorption at 525 nm were 
measured during an alternated irradiation of each inhibitor solution (12.5 µM in 50 mM Tris/acetate 
pH 8.5) with 312 nm light for 30 s and greater than 420 nm light for 15 min. 
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3.4.3 Cloning, Heterologous Expression in E. coli, and Purification of mtPriA 
The gene coding for mtPriA was amplified by PCR using pETM-11-mtPriA[19] as a template 
and cloned into the vector pET24a(+) (Stratagene) via the terminal restriction sites for NdeI 
and XhoI. mtPriA was heterologously expressed in E. coli BL21-Gold cells (Stratagene) 
transformed with pET(24a)(+)-mtpriA. To this end, five liters of Luria Broth (LB) medium 
supplemented with 75 μg/mL kanamycin were inoculated with a pre-culture and incubated 
at 37 °C. After an OD600
 
of 0.6 was reached, the temperature was lowered to 20 °C. 
Expression was induced by adding 0.5 mM IPTG, and growth was continued overnight. Cells 
were harvested by centrifugation (Sorvall/RC5B, GS3, 15 min, 4000 rpm, 4 °C) and 
suspended in 50 mM Tris/HCl pH 8.0, 300 mM NaCl, 10 mM imidazole. After lysing by 
sonication (Branson Sonifier W-250D, 2 x 2 min in 15 sec intervals, 45% pulse, 0 °C), cells 
were centrifuged again (Sorvall/RC5B, SS34, 30 min, 13.000 rpm, 4 °C) to separate the 
soluble from the insoluble fraction of the cell extract. As a first purification step, mtPriA was 
subjected to a Ni2+ affinity chromatography using its C-terminal hexa-histidine tag. To this 
end, the soluble supernatant was loaded onto a HisTrapFF crude column (5 mL; GE 
Healthcare), which had been equilibrated with 50 mM Tris/HCl pH 8.0, 300 mM NaCl, 
10 mM imidazole. After washing the column with the equilibration buffer, a linear gradient 
of 10-500 mM imidazole was applied and mtPriA eluted between 40 and 100 mM imidazole. 
Main fractions were pooled and further purified via size exclusion chromatography. For this 
purpose, a Superdex200 column (HiLoad 26/60, 320 mL, GE Healthcare) was equilibrated 
and operated with 50 mM Tris/HCl pH 8.0, 200 mM sodium chloride, 2 mM dithiothreitol at 
4 °C. Fractions with pure protein were pooled and dialyzed twice against 50 mM Tris/HCl 
pH 8.0. According to SDS-PAGE (12.5% acrylamide), mtPriA was more than 95% pure. 
About 1 mg of protein was obtained per liter of culture. 
 
3.4.4 Steady-state Enzyme Kinetics of mtPriA 
Steady-state enzyme kinetics of the mtPriA reaction were measured spectrophotometrically 
at 300 nm as described.[25] In a coupled enzyme assay the substrate ProFAR was initially 
converted to PRFAR, which was further processed by the enzyme HisF from Thermotoga 
maritima (tmHisF) to yield imidazole glycerol phosphate (ImGP) and aminoimidazole 
carboxamide ribonucleotide (AICAR) (Scheme 3). As ProFAR and PRFAR exhibit identical 
absorption spectra, the second step is indispensible in order to monitor the reaction 
progress at 300 nm (Δε300(ProFAR-AICAR) = 5.637 mM-1cm-1). It furthermore prevents 
product inhibition of the mtPriA reaction.[32] 
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Scheme 3. Coupled enzyme assay for photometric determination of mtPriA activity. 
The steady-state catalytic parameters of mtPriA in the absence of inhibitor were determined 
in triplicate at 25 °C in 50 mM Tris/acetate pH 8.5 in the presence of 100 mM ammonium 
acetate, 2-73 µM ProFAR, and 0.2 µM tmHisF (Table 2). Reactions were initiated with 0.2 µM 
mtPriA, when the baseline signal was constant. To determine the inhibition constants of 
compounds 5-7, 12 and 13 in their open and closed forms, three saturation curves were 
measured in presence of different inhibitor concentrations in each case. Reaction mixtures 
contained 100 mM ammonium acetate, 3-190 µM ProFAR, 0.4-20 µM inhibitor (closed 
inhibitor forms were synthesized photochemically prior to addition to the reaction 
mixture), and 0.04-0.2 µM tmHisF in 50 mM Tris/acetate pH 8.5. Substrate turnover was 
initiated with 0.04-0.2 µM mtPriA. The molar concentration of mtPriA and tmHisF did not 
exceed a tenth of the respective inhibitor concentration. Additionally, to rule out artifacts, 
the photostability of inhibitor 6 was representatively investigated under assay conditions: 
15 µM of 6 in both isomeric forms were irradiated for 30 minutes at 300 nm in the 
spectrophotometer and no change in the absorption spectra was observed. Moreover, it was 
assured that the performance of mtPriA is rate-limiting in each kinetic setup, as doubling of 
its concentration resulted in a doubled initial velocity. Finally, the inhibition constant Ki of 
each DTE compound could be calculated from Formula 1, where Km is the Michaelis constant 
of mtPriA and Kmapp is the apparent Km value determined in the presence of a distinct 
inhibitor concentration c(I). All kinetic parameters are given in Table 2 and steady-state 
enzyme kinetics of 6 in its open and closed form are illustrated in Figure 8. 



( )m
i app
m m
K c I
K
K K
  
Formula 1. Determination of inhibition constant Ki. 
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Figure 8. Substrate saturation curves of mtPriA in the presence of inhibitor 6 in its open (upper 
curves) and closed (lower curves) form. See Table 2 for deduced steady-state kinetic parameters. 
 
Table 2. Steady-state kinetic constants for the ProFAR isomerization activity of mtPriA in absence 
and presence of compounds 5-7, 12 and 13 in their ring-open and ring-closed forms. 
Inhibitor c(I) / µM kcat / s-1 Km / µM Ki / µM 
 open / closed 
-  0.49 
0.49 
0.57 
8.6 
9.2 
8.1 
 
5 5.0 / 5.0 
10.5 / 10.5 
18.0 / 18.0 
0.47 / 0.58 
0.59 / 0.55 
0.55 / 0.60 
12.7 / 13.9 
20.9 / 21.5 
32.5 / 35.2 
10.5 / 8.1 
7.3 / 7.0 
6.5 / 5.8 
6 0.4 / 2.0 
0.6 / 3.5 
0.8 / 8.0 
0.52 / 0.56 
0.59 / 0.60 
0.55 / 0.61 
16.2 / 12.4 
18.7 / 15.9 
18.5 / 23.7 
0.45 / 4.5 
0.51 / 4.1 
0.69 / 4.6 
7 2.0 / 3.5 
3.5 / 7.0 
5.0 / 10.5 
0.47 / 0.58 
0.47 / 0.55 
0.47 / 0.53 
13.1 / 16.2 
17.7 / 24.8 
21.7 / 35.6 
3.8 / 4.0 
3.3 / 3.7 
3.3 / 3.3 
12 1.5 / 4.0 
2.5 / 10.0 
4.0 / 15.0 
0.57 / 0.55 
0.58 / 0.57 
0.60 / 0.55 
16.3 / 15.2 
22.3 / 27.1 
29.4 / 34.9 
1.7 / 5.2 
1.6 / 4.6 
1.7 / 4.9 
13 5.0 / 15.0 
10.0 / 15.0 
15.0 / 20.0 
0.60 / 0.58 
0.60 / 0.57 
0.59 / 0.57 
15.7 / 15.1 
20.7 / 15.0 
26.6 / 14.7 
6.1 / 19.8 
7.1 / 20.2 
7.2 / 28.2 
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Three substrate saturation curves were recorded at different inhibitor concentrations c(I) 
for each form (open/closed). The deduced kcat and Km values are shown. The shown Ki values 
were calculated with Formula 1 from the increase of the apparent Km value with respect to 
the Km value in absence of inhibitor. The mean values and standard deviations of Ki for each 
inhibitor are given in Table 1. 
 
3.4.5 Molecular Modeling 
Energy minimization of the open and closed isomers of compounds 5-7, 12 and 13. 
The conformer distribution of compounds 5, 6, 7, 12 and 13 in their open and closed 
isomers was calculated by Wavefunction Spartan’10[33] using molecular mechanics in water 
(MMFFaq) in the ground state with 20.000 conformers examined, a total charge of -2 for 
phosphonates or -4 for phosphates, singlet multiplicity, subject to symmetry and global 
calculations. Sorted by energy minimum the five best results for each calculation were 
averaged and are shown in Scheme 2. 
Molecular Dynamics (MD) simulations of mtPriA with compound 6 bound in its open 
and closed form. Modeling and MD simulations were performed with YASARA Structure 
Version 13.4.21 employing the YAMBER3 force field.[34] Simulations were run at 298 K 
under periodic boundary conditions and with explicit water, using a multiple time step of 
1 fs for intramolecular and 2 fs for intermolecular forces. Lennard-Jones forces and long-
range electrostatic interactions were treated with a 7.86 Å cutoff, the latter were calculated 
using the Particle Mesh Ewald method.[35] Temperature was adjusted using a Berendsen 
thermostat based on the time-averaged temperature and simulations were carried out at 
constant pressure. The parameterization of the open and closed forms of compound 6 was 
performed using the AM1BCC protocol[36], that assigns atomic charges by applying additive 
bond charge corrections (BCCs) to semi-empirical AM1 atomic charge calculations. Based on 
the crystal structure of mtPriA (PDB ID 3ZS4), the original ligand PRFAR was removed and 
manually replaced by compound 6 in the open and closed form in order to fit the phosphate 
binding pockets. The simulation cell was defined as 5 Å larger than the protein along each 
axis (cell dimensions 52 × 47 × 44 Å3), filled with water to a density of 0.997 g/mL, and 
counterions were added to a final concentration of 0.9% NaCl. The protonation states of 
protein side chains were assigned according to Krieger et al.[37] In order to remove 
conformational stress, two phases of equilibration were conducted: After a 100 ps 
equilibration with frozen protein coordinates, the whole system was equilibrated for 1 ns. 
The two equilibrated models of the open and closed form were subsequently used for the six 
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following (three for each conformer) production MD simulations. To reassign initial atom 
velocities and thus seed independent calculations, the temperature was slightly changed 
(+/-0.0001 K) for the respective second and third simulation runs of the open/closed form. 
Trajectories were sampled at intervals of 100 ps for a total of 10 ns for each model. Each 
snapshot was energy minimized as follows: After removing conformational stress by a 
steepest descent minimization, the procedure continued by simulated annealing (time step 
2 fs, atom velocities scaled down by 0.9 every 10th step) until convergence was reached, i.e. 
the energy improved by less than 0.05 kJ/mol per atom during 200 steps. Binding energies 
were obtained for each energy minimized snapshot using YASARA’s integrated binding 
energy function that computes the energetic difference of the ligand at bound state and at 
infinite distance from its binding site. Representative enzyme models (shown in Figure 4) 
for each simulation are based on the energy minimized snapshots with the best binding 
energy. The ligand binding energies and standard deviations (see Table 3) were calculated 
by using the full production trajectory. 
 
Table 3. Ligand binding energies derived from MD simulations of mtPriA and compound 6 in its 
open and closed form.[a] 
 
Ligand binding energy (open) 
[kJ/mol] 
Ligand binding energy (closed) 
[kJ/mol] 
run 1 -2171 ± 55 -2062 ± 64 
run 2 -2162 ± 59 -1919 ± 71 
run 3 -2122 ± 77 -2049 ± 60 
[a] Three independent simulations were performed in each case; see Experimental Methods for 
details.  
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CHAPTER 2 
 
 
4 TOWARDS PHOTOSWITCHABLE KINASE INHIBITORS† 
                                                             
† Synthesis and characterization of new compounds, photochemical investigations and Molecular 
Modeling by Natascha Kuzmanovic. Whole-cell dose response experiments and luminescent ERK2 
activity assay by Nuška Tschammer (University of Erlangen). Morten Grøtli (University of 
Gothenburg) supervised the Molecular Docking and instructed the radiometric ERK2 activity assay at 
Millipore UK Ltd. Burkhard König supervised the project. 
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4.1 Introduction 
The detailed understanding how molecular mechanisms proceed during cell signal 
transduction remains an important topic of cell biology. Phosphorylation by protein kinases 
is one of the most frequent modes to regulate vital processes in the human body like gene 
expression, protein translation, cell cycle progression and apoptosis.[1] More than 500 
different protein kinases are encoded in the human genome.[2] As components of cellular 
cascade systems they mediate each other sequentially (cf. Figure 9), usually by transferring 
the γ-phosphate of adenosine triphosphate (ATP) covalently to serine, threonine or tyrosine 
hydroxides of their specific substrates. It has been assessed that malfunction of the kinases 
contributes to human diseases including obesity, diabetes, rheumatoid arthritis, 
neurodegenerative disorders and cancer.[2-4] Kinases are therefore one of the most 
important targets in drug discovery but the information on the exact mechanisms of 
molecular control is still limited.[3, 5] 
The extracellular-regulated kinase (ERK) pathway (Figure 9) plays a central role in cancer 
research as it controls the growth and survival of a broad spectrum of human tumors.[6] 
When growth factors bind extracellularly to a specific transmembrane receptor they launch 
signal transduction through the protein kinase cascade Ras-Raf-MEK-ERK. ERK occurs 
either as ERK1 or ERK2, which are closely related to each other (84% sequence identity) 
and share many if not all functions; they are therefore usually referred to as ERK1/2.[7] As 
pivot of this cascade, ERK1/2 activates transcription factors in the cell nucleus to initiate 
protein expression, cell proliferation, or apoptosis.[7] Inhibiting ERK1/2 thus allows for new 
anti-tumor treatments and several inhibitors are currently subjected to clinical trials.[8] 
However, deciphering the mechanisms of the ERK pathway continues to be an important 
and challenging task.[4, 7] 
 
Figure 9. The extracellular-regulated kinase (ERK) pathway.  
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The development of remote-controllable, fast-acting and selective ERK1/2 inhibitors may 
provide a convenient tool to further investigate the dynamic operation and time-dependent 
parameters for signaling output. As outlined in Chapter 1, the regulation of biomolecules by 
light has gained a rapidly growing interest in science.[9-11] Most examples include 
azobenzene units due to easy synthetic access, high photostability and ultrafast kinetics. 
Exploiting their quick response nature, photoswitchable ion channel or receptor ligands 
were developed to reversibly control neuronal activity.[12-15] However, their performance is 
limited because they do not allow a complete photoconversion and the thermal cis to trans 
reisomerization is fast.[12] In contrast, photoswitchable molecular tools based on the 1,2-
dithienylethene (DTE) scaffold exhibit high photostationary states and thermal stability of 
both photoisomers in the dark,[16] which makes them ideal candidates for the light-
dependent control of rather slow biological processes such as enzymatic reactions or DNA 
hybridization.[17-24] 
            
Scheme 4. Light-induced switching of a DTE between its open isomer and closed isomer.  
Irradiation with UV or visible light, respectively, toggles DTEs between the open and the 
closed photoisomer (Scheme 4). Selective ATP competitive ERK1/2 inhibitors (Figure 10) 
and the open isomer share similar shapes which correlate in size and electronics.[25-26] 
Equipped with suitable hydrogen bonding motifs the DTE may join the ATP binding site of 
the kinase and thereby inhibit enzyme activity. As the conformation of the respective closed 
isomer is far more rigid (Scheme 4), its affinity to the catalytic center is expected to be 
reduced, which in turn enhances kinase activity. Hence we aimed to develop DTE based 
ERK1/2 inhibitors, which toggle kinase activity upon irradiation with light. Our desired 
photoswitchable kinase inhibitors should allow for the non-invasive, reversible remote-
control of cellular kinase function in real time and thereby provide a convenient tool to 
deepen the understanding of cellular signal mechanisms. Based on these studies new 
methods of anticancer therapy could be established. 
 
Figure 10. Selective ERK2 inhibitors with IC50 values in brackets.[25-26]  
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4.2 Results and Discussion 
4.2.1 Molecular Docking 
In order to design photoswitchable kinase inhibitors, suitable DTE based structures were 
virtually screened. The binding mode and affinity between small-molecule ligands and the 
kinase receptor were calculated by Molecular Docking.[27] ERK2 (PDB ID 1TVO) was used as 
receptor grid and the library of ligands consisted of open and closed isomer 
dithienylcyclopentene derivatives with different short hydrogen bonding motifs at their 
thiophene moieties. Hits were identified by scoring function and chosen manually, whereby 
the binding mode and affinity of the respective open/-closed photoisomer pairs must differ 
significantly. The compounds drawn in Figure 11 adopted similar positions as the co-
crystallized ligand FR180204 in the catalytic site (Figure 12). Concurrently, their particular 
ring-closed counterparts were randomly distributed as result of weak interactions with the 
designed grid area of the enzyme. 
 
Figure 11. DTEs 1-7 were identified as hits after virtual screening with ERK2 receptor (PDB ID 1TVO). 
Their respective ring-closed isomers afforded significantly lower docking scores. 
 
Figure 12. Binding mode of the ring-open DTE 3 (green) in the ATP binding pocket of the target 
kinase ERK2. Left: four hydrogen bonds to the protein are indicated in yellow. Right: superposition of 
3 with reference ligand FR180204 (grey), the protein surface is shown as grey shadows.  
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4.2.2 Synthesis 
The desired photoswitchable kinase inhibitors were prepared via bischloro-DTE 11 and 
chloro-phenyl-DTE 12 according to literature known procedures (Scheme 5).[28-29] Starting 
with chlorination of 2-methyl-thiophene 8, subsequent Friedel-Crafts acylation followed by 
McMurry coupling led to compound 11 in moderate to good yields (58-79%). Further 
modification to obtain compound 12 was accomplished by Suzuki coupling (64% yield). 
 
Scheme 5. Synthesis of the bischloro-DTE 11 and chloro-phenyl-DTE 12 as precursors for further 
derivatization. 
In order to afford carboxy-DTEs 1 and 5, the chlorine atoms of compounds 11 and 12 were 
transformed into carboxylic acids via lithium halide exchange with n-butyl lithium, followed 
by treating with gaseous carbon dioxide and acidic work-up (Scheme 6). Reactions achieved 
very good yields of 98 to 99%. Acidic esterification of 1 and 5 in methanol led to methyl 
ester-DTEs 2 and 6 in excellent yields of 94 to 96%. DTEs 1 and 5 were treated with thionyl 
chloride and subsequently converted into either amide or methyl ester residues using 
gaseous ammonia in anhydrous THF to yield DTEs 3 and 7 (61-71%) or a solution of 
ammonia in methanol to access DTE 4 (35%). 
 
Scheme 6. Synthetic pathway to access the target DTEs 1-7. 
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4.2.3 Photochromism 
The photochemical properties of the target DTEs 1-7 were spectrophotometrically studied. 
All title compounds exhibited excellent photochromic behavior in methanol solutions. 
Figure 13 shows exemplarily the UV/Vis absorption spectra evolution of compound 4 upon 
irradiation with 312 nm light in periods of 6 s. The absorption band at 260 nm decreases 
and two new maxima arise at around 355 and 525 nm, which results from the ring-closed 
isomer formation, and turns the initially colorless solution pink (Figure 13). The 
photostationary states (PS) are reached after 36 to 72 s of UV irradiation (Table 4, appendix 
Figure A1). Exposure to visible light (> 420 nm) induces the reopening, which is usually 
complete after 15 min and can be observed by decoloration and return to the original 
spectrum. 
 
 
Figure 13. Light-induced interconversion of compound 4 between its open and closed isomer and 
its UV/Vis absorption spectra evolution (50 µM in MeOH) upon irradiation with 312 nm light; arrows 
indicate the changes of the absorption maxima with irradiation periods of 6 s; the colors of the 
respective solutions are depicted. 
The cycle performance of the title compounds 1-7 was studied by alternately irradiation 
with 312 nm and greater than 420 nm light. Figure 14 depicts the photostability of DTE 4 
with a high fatigue resistance of 91% after eight ring-closing/-opening cycles. The spectra 
for DTEs 1-3 and 5-7 are included in the appendix in Figure A2 with moderate to good 
fatigue resistance rates ranging from 62 to 83% (Table 4). 
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Figure 14. Cycle performance of compound 4. Changes in absorption at 525 nm were measured 
during an alternated irradiation of the inhibitor solution (50 µM in MeOH) with 312 nm light for 60 s 
and greater than 420 nm light for 15 min. 
Table 4 summarizes the photochemical properties of the target DTEs 1-7 including the time 
of UV irradiation to reach the PS (tPS), the fatigue resistance after recording eight ring-
closing/-opening cycles, and the thermal stability of the closed photoisomers. We could not 
observe any consistent correlation between substitution pattern and the examined 
parameters. 
Table 4. Photochemical properties of the target DTEs 1-7.  
Compound tPS [s] 
Fatigue 
resistance[a] [%] 
Thermal 
stability[b] [%] 
1 54 75 37 
2 66 83 46 
3 72 80 31 
4 42 91 36 
5 54 79 52 
6 60 66 77 
7 36 62 48 
[a] after 8 cycles, [b] after storage in 10 mM DMSO solutions for 6 months at -20 °C in the dark. 
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4.2.4 Biological Test Results 
Whole-cell dose response experiments. 
To study the inhibitory activity of the photoswitchable kinase inhibitors 1-7 a whole-cell 
reporter gene assay was performed.[30] Thereby, the ERK1/2 activity of HEK cells was 
detected at distinct amounts of inhibitor to generate dose response curves. Initially, 
neurotensin stimulates the neurotensin receptor 1 to launch the phosphorylation cascade, 
which activates ERK1/2 further downstream. Activated ERK1/2 in turn phosphorylates the 
transcription factor Elk1, which leads to accumulation of luciferase in the cell. The 
luminescence signal is thus proportional to ERK1/2 activation and a reduced luminescence 
indicates the inhibition of ERK1/2. The inhibitory activity of DTEs 1-7 against ERK1/2 was 
examined as open and closed isomers separately. We irradiated the photoswitches prior to 
incubation of the cells. The experiments were performed in the dark and the ERK2 inhibitor 
FR180204 was used as reference.  
 
Figure 15. Inhibition curves of 4 in its open (blue) and closed (red) isomer. The reference inhibitor 
FR180204 is marked in grey.  
We observed that all compounds were sufficiently transported into the cells as determined 
by UV/Vis absorption measurements of the cell lysate after centrifugation. Figure 15 shows 
exemplarily the inhibition curves of DTE 4 in its open (IC50 13 µM) and closed isomer 
(IC50 n.a.). Indeed, the design concept seems viable regarding the distinct performances of 
the two isoforms. Table 5 summarizes the test results for all inhibitors 1-7 and the 
particular dose response curves for DTEs 1-3 and 5-7 are included in the appendix in Figure 
A3. The open isomer compounds of DTEs 1-4 and 7 achieved inhibition constants in the 
micromolar range, while only DTE 2, 4 and 7 reached the efficacy of the reference inhibitor. 
Their respective closed isomers were solely active at the highest concentration, which may 
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indicate cytotoxity. However, we could not observe any toxic effects of the ring-open 
isomers. DTEs 5 and 6 exhibited not enough activity at the concentrations applied. Taken 
together, these results confirm efficient photoswitchable activities of the designed 
molecules 2, 4 and 7 within the ERK cascade in HEK cells. Nevertheless, cells contain a 
complex machinery of various factors, which could response to interaction with the DTEs 
and generate the observed signal. We hence performed further in vitro investigations to 
support the observed findings. 
Table 5. Test results of whole-cell dose response experiments. The open-isomers of 1-7 were tested 
three times in triplicate, and their respective closed isomers two times in triplicate for each 
concentration. 
 
open closed 
Compound 
IC50 
[M] 
pIC50  SE Efficacy [%] 
IC50 
[M] 
pIC50  SE Efficacy [%] 
FR180204 3.8 5.42  0.02 100 - - - 
1 4.9 5.31  0.33 17  4 2.3 5.64  0.46 16  3 
2 20 4.69  0.06 99  2 41 4.39  0.07 94  2 
3 5.9 5.23  0.43 14  4 > 50 < 4.30 60 (@ 50 M) 
4 13 4.89  0.05 96  2 n.a. n.a. n.a. 
5 > 50 < 4.30 45 (@ 50 M) n.a. n.a. n.a. 
6 > 50 < 4.30 45 (@ 50 M) n.a. n.a. n.a. 
7 16 4.79  0.07 100  2 37 4.43  0.10 98  2 
 
 
Radiometric kinase activity assay 
To approve the photoswitchable kinase inhibition, a radiometric in vitro ERK2 activity assay 
was employed at  Millipore UK Ltd.[31] DTE 4 was exemplarily prepared as ring-open or ring-
closed forms, which were incubated with isolated ERK2, radioactive γ-33P-ATP and a 
peptidic substrate in the dark. The signal is detected by scintillation counting of the 
resulting radioactive peptide and correlates positively with kinase activity. Indeed, the test 
results confirmed inhibitory activity against ERK2 (Figure 16). Surprisingly, no significant 
difference in the behavior of the two isoforms could be observed (Figure 16). Insufficient 
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geometric diversity of the photoisomers could either be the reason or the two curves could 
be caused by the same molecule as result of reisomerization. The latter is presumably the 
case since the observed IC50 of 28 µM for both isoforms matches to the open isomer data of 
the whole-cell approach. At a first glance, the thermal reopening outlined in Table 4 may be 
responsible, but considering the interactions in the enzyme’s active site, enzymatic 
reisomerization is also imaginable. 
   
Figure 16. Inhibition curves of DTE 4 in its open (left) and closed (right) photoisomer against ERK2. 
 
Enzymatic reisomerization studies 
In order to exclude the influence of the enzyme on the ring-opening reaction, ERK2 
(0.12 µM, 0.5 µg/mL in HEPES buffer, pH 7.50) was incubated with the closed photoisomers 
of compound 4 (50 µM) and the changes were followed photometrically over 16 h. To 
quantify unspecific protein interactions the inhibitor’s behavior was additionally studied in 
presence of BSA (75 nM, 0.5 µg/mL), a serum albumin which usually acts as standard. 
 
Figure 17. The influence of the proteins ERK2 and BSA on the ring-closing/-opening reaction of DTE 4 
was photometrically recorded over 16 h. 
ERK2 vs. DTE 4 open ERK2 vs. DTE 4 closed 
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In comparison with buffer environment, the absorbance of the ERK2 inhibitor 4 decreased 
slightly faster in presence of a protein. We could not observe any proof for specific 
interaction with ERK2 since incubation of BSA resulted in comparable curves (Figure 17). 
The influence of proteins on the equilibrium of the photoisomers is negligibly slow 
compared to kinase activity under assay conditions. Thus we could not assess any 
correlation between the enzyme activity test results and enzymatic reisomerization. 
Consequently, the thermal reopening (Table 4) of the closed forms is considered to be 
responsible for the observed trend. To generate reliable results, the photoswitch probes 
require fresh preparation by illumination with the respective light source. 
 
Luminescent kinase activity assay 
To circumvent the storage and transport duration of the externally employed radiometric 
assay, a commercially available luminescent kinase activity assay was analogously 
performed using freshly prepared photoswitch solutions.[32] Isolated ERK2 was incubated 
with the open and closed forms of the DTEs 1-7 straight after irradiation. The assay 
measures the amount of ADP formed by the kinase reaction. ADP is subsequently converted 
to ATP, which in turn generates light using the luciferase/luciferin reaction. Thus, the 
luminescent signal correlates positively with the ADP amount and kinase activity. The 
resulting curves exhibit a sigmoidal shape, but surprisingly with increasing output signal 
(Figure 18), which could not be explained so far. Based on these studies the inhibitory 
effects of the whole-cell approach could not be confirmed against isolated ERK2. Given the 
vast numbers of enzymes, receptors and other participants involved in the ERK pathway, it 
remains challenging to identify the anchor point, where and how the designed DTEs 
interfere in cell signaling. 
 
Figure 18. Test results of the in vitro luminescent ERK2 kinase activity assay.  
FR180204 
 
  DTEs 1-7 
  Towards Photoswitchable Kinase Inhibitors 
   
 47 
4.3 Conclusion 
In summary, we have developed a series of photochromic dithienylcyclopentenes which 
showed light-dependent cell signaling inhibition addressing the extracellular-regulated 
kinase pathway. The structural design of the envisaged ATP competitive kinase inhibitors 
was derived from Molecular Docking calculations using ERK2 as target protein. Several 
suitable inhibitors were synthesized and photochemically studied exhibiting fast 
photoconversion, moderate to high fatigue resistance rates, but only moderate thermal 
stability. To generate reliable results, it was thus absolutely essential to irradiate the 
photoswitch probes straight before testing.  Their inhibitory activity was investigated by 
different enzyme activity assays. A commercially available whole-cell assay provided 
inhibition constants in the micromolar range for the ring-open photoisomers of several 
DTEs. After photoisomerization by UV light, their inhibitory activity dropped and cytotoxic 
effects were observed. Unfavorably, we could not confirm these findings by incubation of 
isolated ERK2. The affected site, where our inhibitors interfere in the cellular ERK pathway, 
was not identified yet. In order to gain further insight, their activity needs to be investigated 
separately towards all tiers of the ERK cascade. As ERK1/2 plays the key role in the ERK 
pathway, it remains a pivotal element of cancer research to identify the enzyme’s exact 
functioning in the complex cellular phosphorylation networks.  
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4.4 Experimental Materials and Methods 
4.4.1 Synthesis and Characterization of New Compounds 
General. Commercial reagents and starting materials were purchased from Acros Organics, 
Alpha-Aesar, Fluka, Sigma Aldrich or VWR and used without further purification. Solvents 
were used in p.a. quality and dried according to common procedures, if necessary. 
Compounds 1, 2, 5, 11 and 12 were prepared according to previously reported 
procedures.[28-29] Flash column chromatography was performed on a Biotage Isolera One 
automated flash purification system with UV/Vis detector using Sigma Aldrich MN silica gel 
60 M (40-63 µm, 230-400 grain diameter) for normal phase or pre-packed Biotage SNAP 
cartridges (KP-C18-HS) for reversed phase chromatography. Reaction monitoring via TLC 
was performed on alumina plates coated with silica gel (Merck silica gel 60 F254, 0.2 mm). 
Melting points were determined using a Stanford Research Systems OptiMelt MPA 100. NMR 
spectra were recorded on Bruker Avance 300 (1H 300.13 MHz, 13C 75.48 MHz) and Bruker 
Avance 400 (1H 400.13 MHz, 13C 100.61 MHz) instruments. The spectra are referenced 
against the NMR-solvent, chemical shifts δ are reported in ppm and coupling constants J are 
given in Hz. Resonance multiplicity is abbreviated as: s (singlet), d (doublet), t (triplet), m 
(multiplet) and b (broad). Carbon NMR signals are reported using DEPT 135 spectra with 
(+) for primary/tertiary, (−) for secondary and (q) for quaternary carbons. Mass spectra 
were recorded on Finnigan MAT95 (EI-MS), Agilent Q-TOF 6540 UHD (ESI-MS, APCI-MS), 
Finnigan MAT SSQ 710 A (EI-MS, CI-MS) or ThermoQuest Finnigan TSQ 7000 (ES-MS, 
APCI-MS) spectrometer. UV/Vis absorption spectroscopy was performed using a Varian 
Cary BIO 50 UV/Vis/NIR spectrometer. IR-spectra were recorded with a Specac Golden Gate 
Diamond Single Reflection ATR System in a Bio-Rad FT-IR-Spectrometer Excalibur FTS 
3000. Signal intensity is abbreviated with s = strong, m = medium and w = weak.  
Photochemistry. Standard hand-held lamps (Herolab, 312 nm, 6 W) were used for 
visualizing TLC plates and to carry out the ring-closure reactions at 312 nm. The ring-
opening reactions were performed with the light of a 200 W tungsten light bulb which was 
passed through a 420 nm cut-off filter to eliminate higher energy light. The power of the 
light is given based on the specifications supplied by the company when the lamps were 
purchased. A light detector was not used to measure the intensity during the irradiation 
experiments. 
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4,4'-(Cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-2-methyl ester) (2). Biscarboxy 
dithienylcyclopentene 1 (500 mg, 1.43 mmol) was dissolved in methanol (150 mL) and 
eight drops of HCl (conc.) were added. The brown solution was heated to 85 °C for 4 days. 
After evaporating the solvent in vacuo the crude product was purified by flash column 
chromatography (PE/EtOAc 1:2) yielding 505 mg (1.34 mmol, 94%) of compound 2 as 
brown oil; 1H-NMR (400 MHz, CDCl3): δ = 1.90 (6H, s, 2 thiophene-CH3), 2.05 (2H, q, J = 
7.5 Hz, cyclopentene-CH2), 2.77 (4H, t, J = 7.5 Hz, 2 cyclopentene-CH2), 3.84 (6H, s, 
2 COOCH3), 7.50 (2H, s, thiophene-H); 13C-NMR (100 MHz, CDCl3): δ = 14.8 (+), 22.8 (–), 
38.6 (–), 52.0 (+), 129.2 (q), 134.4 (+), 134.7 (q), 136.6 (q), 142.8 (q), 162.6 (q); UV/Vis: 
open isomer: max = 260 nm, closed isomer: max = 355, 540 nm; MS (EI): m/z (%) = 
84.0 (100), 376.1 (26, M+·); HR-MS (ESI): calcd. for C19H20O4S2 377.0876; found 377.0870. 
 
4,4'-(Cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-2-carboxamide) (3). Biscarboxy 
dithienylcyclopentene 1 (250 mg, 0.72 mmol) was dissolved in dry THF (50 mL) under 
nitrogen atmosphere and treated with thionyl chloride (0.21 mL, 2.87 mmol) and 4 drops of 
DMF. After stirring the reaction mixture for 20 h at room temperature under nitrogen 
atmosphere the solvent and thionyl chloride were removed in vacuo. The brown residue 
was dissolved in dry THF (50 mL) and gaseous ammonia was bubbled through for 15 min by 
precipitation of NH4Cl which was removed by filtration. After removing the solvent under 
reduced pressure the crude product was intensively washed with chloroform and water 
over a filter until the filtrate turned colorless. Dissolving the filtration residue in acetone 
and removing the solvent under high vacuum yielded 51 mg (0.15 mmol, 21%) of compound 
3 as colorless solid; m.p.: 223 °C; 1H-NMR (400 MHz, acetone-d6): δ = 1.94 (6H, s, 2 CH3), 
2.10 – 2.03 (2H, m, cyclopentene-CH2), 2.81 (4H, t, J = 7.5 Hz, 2 cyclopentene-CH2), 7.50 (2H, 
s, 2 thiophene-H); 13C-NMR (100 MHz, acetone-d6): δ = 14.7 (+), 23.5 (–), 39.1 (–), 
130.4 (+), 135.6 (q), 136.8 (q), 137.3 (q), 140.8 (q), 163.7 (q); UV/Vis: open isomer: max = 
260 nm, closed isomer: max = 350, 525 nm; MS (EI): m/z (%) = 693.1 (100) [2MH+], 
346.9 (60) [MH+], 363.9 (50) [MNH4+]; HR-MS (ESI): calcd. for C17H18N2O2S2 347.0882; 
found 347.0877. 
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Methyl 4-(2-(5-carbamoyl-2-methylthiophen-3-yl)cyclopent-1-enyl)-5-methyl-thio- 
phene-2-carboxylate (4). Bismethylester dithienylcyclopentene 2 (100 mg, 0.27 mmol) 
was dissolved in a solution of ammonia in methanol (7 N, 40 mL) in an autoclave vessel. 
After sealing in an autoclave, the brown solution was heated to 110 °C for 17 h generating 
pressure of 5 bar. The solvent and the ammonia were removed by nitrogen stream. The 
crude product was purified by flash column chromatography (PE/EtOAc 1:2) yielding 38 mg 
(0.11 mmol, 39%) of compound 4 as brown foam; 1H-NMR (300 MHz, CDCl3): δ = 1.91 (3H, 
s, thiophene-CH3), 1.94 (3H, s, thiophene-CH3), 2.05 (2H, p, J = 7.5 Hz, cyclopentene-CH2), 
2.77 (4H, t, J = 7.5 Hz, 2 cyclopentene-CH2), 3.83 (3H, s COOCH3),  5.93 (2H, bs, CONH2), 7.22 
(1H, s, thiophene-H), 7.50 (1H, s, thiophene-H); 13C-NMR (75 MHz, CDCl3): δ = 14.8 (+), 
22.9 (–), 38.5 (–), 52.0 (+), 129.2 (q), 130.6 (+), 133.2 (q), 134.5 (+), 134.8 (q), 136.5 (q), 
141.2 (q), 142.9 (q), 162.6 (q), 162.8 (q); UV/Vis: open isomer: max = 260 nm, closed 
isomer: max = 355, 540 nm; MS (EI): m/z (%) = 361.1 (100, M+·), 301.1 (97, M+·-COOMe); 
HR-MS (ESI): calcd. for C18H19NO3S2 362.0879; found 362.0875. 
 
Methyl 5-methyl-4-(2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-en-1-yl)thio- 
phene-2-carboxylate (6). Monocarboxy-DTE 5 (100 mg, 0.26 mmol) was dissolved in 
methanol (25 mL) and treated with 3 drops of HCl (conc.). It was heated to reflux for 72 h. 
The solvent was removed at the rotary evaporator and the crude mixture was purified by 
flash column chromatography (PE/EtOAc 19:1) yielding 98 mg (0.25 mmol, 96%) of 
compound 6 as red oil; 1H-NMR (400 MHz, CDCl3): δ = 1.94 (3H, s, CH3), 1.95 (3H, s, CH3), 
2.13 – 2.03 (2H, m, cyclopentene-CH2), 2.89-2.75 (4H, m, 2 cyclopentene-CH2), 3.85 (3H, s, 
C(O)OCH3), 6.97 (1H, s, thiophene-H), 7.23 (1H, t, J = 7.4 Hz, phenyl-H), 7.33 (2H, t, J = 7.6 Hz, 
2 phenyl-H), 7.48 (2H, d, J = 8.2 Hz, 2 phenyl-H), 7.58 (1H, s, thiophene-H); 13C-NMR: 
(100 MHz, CDCl3): δ = 14.4 (+), 14.8 (+), 22.9 (–), 38.6 (–), 52.0 (+), 123.7 (+), 125.3 (+), 
127.1 (+), 128.8 (+), 128.9 (q), 133.6 (q), 134.3 (q), 134.4 (q), 134.7 (+), 135.8 (q), 136.3 (q), 
137.0 (q), 140.0 (q), 143.0 (q), 162.7 (q); UV/Vis: open isomer: max = 265, 295 nm, closed 
isomer: max = 255, 295, 355, 540 nm; MS (ESI): m/z (%) = 395.1 (100, MH+·); HR-MS (ESI): 
calcd. for C23H22O2S2 395.1134; found 395.1133. 
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5-Methyl-4-(2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-en-1-yl)thiophene-2-
carboxamide (7). Monocarboxy-DTE 5 (100 mg, 0.26 mmol) was dissolved in dry THF 
(25 mL) under nitrogen atmosphere and treated with thionyl chloride (38 µL, 0.53 mmol) 
and 2 drops of DMF. After stirring the reaction mixture for 17 h at room temperature under 
nitrogen atmosphere the solvent and thionyl chloride were removed in vacuo. The residual 
blue oil was dissolved in dry THF (25 mL) and gaseous ammonia was bubbled through for 
15 min by precipitation of NH4Cl and a color change of the solution from blue to purple. It 
was diluted with diethyl ether (10 mL), washed with water (15 mL) and the phases 
separated. The aqueous phase was extracted twice with diethyl ether (10 mL) and the 
combined organic phases dried over MgSO4 and the solvent removed at the rotary 
evaporator. Purification was performed by flash column chromatography (PE/acetone 4:1) 
yielding 66 mg (0.17 mmol, 67%) of compound 7 as purple foam; 1H-NMR: (400 MHz, 
CDCl3): δ = 1.95 (3H, s, CH3), 2.02 (3H, s, CH3), 2.14 – 2.04 (2H, m, cyclopentene-CH2), 2.87 – 
2.73 (4H, m, cyclopentene-CH2), 5.68 (2H, bs, C(O)NH2), 6.98 (1H, s, thiophene-H), 7.25 – 
7.20 (1H, m, phenyl-H), 7.25 (1H, s, thiophene-H), 7.34 (2H, t, J = 7.6 Hz, 2 phenyl-H), 7.48 
(2H, d, J = 8.2 Hz, 2 phenyl-H); 13C-NMR: (100 MHz, CDCl3): δ = 14.4 (+), 14.9 (+), 23.0 (–), 
38.4 (–), 38.5 (–), 123.7 (+), 125.3 (+), 127.1 (+), 128.9 (+), 130.8 (+), 132.8 (q), 133.7 (q), 
134.3 (q), 134.5 (q), 135.9 (q), 136.3 (q), 136.9 (q), 140.1 (q), 142.3 (q), 163.7 (q); UV/Vis: 
open isomer: max = 265, 290 nm, closed isomer: max = 255, 295, 355, 525 nm; MS (ESI): 
m/z (%) = 380.1 (100, MH+·), 759.2 (67, 2 MH+·); HR-MS (ESI): calcd. for C22H21NOS2 
380.1137; found 380.1138. 
 
4.4.2 Molecular Docking 
The crystal structure of ERK2 (PDB code 1TVO) with a co-crystallized receptor was 
retrieved from RCSB protein data bank and used as target structure for docking studies. The 
Protein Preparation Wizard of MacroModel (Maestro v. 9.0) was applied to prepare the 
enzyme for Glide calculations, which were performed by Glide XP (Maestro v. 9.0) to 
generate the receptor grid. Energy minimizations (Polak-Ribiere conjugate gradient 
minimization, maximum of 5000 iterations) and conformational searches (systematic 
torsional sampling in water, maximum of 5000 steps) were provided by MacroModel for a 
series of DTE based derivatives. They were docked as ligands into the protein grid by 
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standard precision (SP) and extra precision (XP) modes with OPLS2005 as force field. The 
energy window for saving structures was set to 10 kJ/mol. 
 
4.4.3 Photochemical Investigations 
Photochemical syntheses of ring-closed isomers. Solutions of compounds 1-7 in MeOH 
(50 µM) were irradiated with a 312 nm lamp until complete conversion (36 s to 72 s) 
yielding pink solutions containing the ring-closed isomers. The changes in the UV/Vis 
absorption spectra are representatively shown for compound 4 in Figure 13 and for 
compounds 1-3 and 5-7 in the appendix in Figure A1. 
Fatigue resistance studies. In order to test the robustness of the photochromic systems, 
photochemical cycling studies were recorded for all switches (see Figure 14 and appendix, 
Figure A2). In each case, a solution of ring-open inhibitor in MeOH (50 µM) was alternately 
irradiated with 312 nm light for 60 s and with visible light for 15 min over eight cycles. The 
absorption change at 525 nm was recorded after each cycle and plotted against the cycle 
number. 
Thermal stability measurements: Absorption spectra were recorded in MeOH solutions 
(50 µM) in quartz cuvettes. Absorbances were recorded at 525 nm after storing the closed 
isomer compounds for 6 months at -20 °C in the dark and after subsequent UV irradiation 
for full photoconversion. The quotient of these two values gives the amount of closed 
isomer. 
 
4.4.4 Enzymatic Reisomerization with ERK2 
Purchased enzyme: ERK2/MAPK1, human recombinant, expressed in E.coli, untagged; 
41.76 kDa, 0.223 mg/mL, 296.000 pmol/mg x min (=> 17.76 nm/µg in 1 hour). DTE 4 was 
dissolved in DMSO (10 mM, 1 mL DMSO) and diluted 1:200 with buffer (50 mM HEPES, 
pH 7.50, 100 mM NaCl, 5 mM DTT, 20% glycerol) giving a final DTE concentration of 50 µM. 
Buffer solutions of BSA (75 nM, 0.5 µg/mL) and ERK2 (0.12 µM, 0.5 µg/mL) were prepared. 
ERK2, BSA or buffer was incubated with the DTEs as open and closed isomers, respectively, 
and the absorbance at 260 nm (max of open isomer) and 525 nm (max of closed isomer) 
recorded over 16 h with time intervals of 30 min. Pure Buffer, BSA and ERK2 solutions were 
used to quantify the background absorption. Measurements were performed in triplicates in 
a 96-well Greiner flat bottom microtiter plate.   
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CHAPTER 3 
 
 
5 SYNTHESIS OF PHOTOCHROMIC DITHIENYLMALEIMIDE AMINO 
ACIDS‡ 
 
                                                             
‡ Design, synthesis, characterization and peptide coupling experiments of new compounds by 
Natascha Kuzmanovic. Optimization of synthesis protocols and photophysical investigations by 
Daniel Wutz. Burkhard König supervised the project. 
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5.1 Introduction 
Over the last decade photochromic molecules have increasingly been applied in biology to 
alter conformations or switch functions by light.[1-3] Photoinduced activation or deactivation 
of biomolecules, particularly with visible light, provides a high spatial and temporal 
resolution and is therefore a convenient method for investigating cellular processes or 
pathogeneses.[4] Two main concepts are applied: the irreversible release of caged 
compounds bearing photocleavable protecting groups[5] or the reversible switching 
between two structurally different photoisomers[6] (photoswitches) by light of certain 
wavelengths. In the latter field, most structures are based on azobenzene units due to easy 
synthetic access, high photostability and ultrafast kinetics.[7] The light-controlled regulation 
of neuronal activity by azobenzene containing ligands for ion channels and receptors were 
recently reported.[8-10] However, the photophysical properties of azobenzenes do not allow a 
complete photoisomerization in the photostationary state and in many cases the cis to trans 
thermal re-isomerization is fast.[7] Photochromic compounds based on the 
1,2-dithienylethene (DTE) scaffold show nearly quantitative photochemical conversion and 
both photoisomers are thermally stable in the dark.[11] DTEs have been used to control 
enzyme activity,[12-15] Watson-Crick base pairing,[16-18] and even the agility of a living 
organism.[19] Irradiation with UV or visible light, respectively, toggles DTEs between the 
open and the closed photoisomer, which differ in conformational flexibility and electronic 
conjugation (Figure 19). Despite their interesting photophysical properties the application 
of DTEs as photoswitches in life science is still limited. The synthesis, particular of non-
symmetric DTEs is laborious[18, 20] and the water-solubility of the typically used hydrophobic 
diaryl (perfluoro-)cyclopentene core is limited. Hence, we decided to develop a non-
symmetric dithienylmaleimide based amino acid, which could easily be incorporated in any 
peptide by solid phase peptide synthesis (SPPS). 
 
Figure 19. Photochemical interconversion of a DTE with cyclopentene, perfluoro-cyclopentene or 
maleimide ring structure. 
DTEs with a central maleimide unit have been reported that are efficiently prepared via 
Perkin condensation allowing non-symmetric substitution of the thiophene rings.[21] 
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Compared to diarylcyclopentenes, the diarylmaleimides exhibit a higher hydrophilicity and 
hence offer a better water solubility. Meanwhile the diarylmaleimide’s absorption maxima 
are shifted to higher wavelengths. The photoisomerization can thus be induced by light with 
lower energy reducing potential cell damage.[11]  oreover, the diarylmaleimides’ 
biocompatibility is known from bisindoylmaleimides, e.g. the arcyriarubins and 
arcyriaflavins with antibiotic activities against bacteria and fungi, and several other highly 
potent protein kinase inhibitors.[22-26] Therefore the dithienylmaleimide structure was 
selected for the synthesis of a photoswitchable amino acid. The building block, Alloc 
protected at the amino group and with free carboxylic acid, is readily incorporated in 
peptides by solid phase synthesis as illustrated in Figure 20. 
 
Figure 20. SPPS of the dithienylmaleimide amino acid 1 and natural amino acids (bowls). 
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5.2 Results and Discussion 
5.2.1 Synthesis 
To synthesize the amino acid functionalized dithienylmaleimide 2, we chose to form the 
maleimide core by Perkin condensation allowing us to independently equip the thiophene 
precursors 3 and 4 with the desired amino or carboxylic group, respectively (Scheme 7).[21, 
27-28] The glyoxylamide thiophene 3 carries the N-terminal amine via a methylene linker, 
which was necessary to introduce as all attempts to directly introduce the nitrogen atom at 
the thiophene failed.[29] Alloc was chosen as amino protecting group due to its stability 
against the applied conditions of further synthetic steps towards compound 2. Furthermore, 
deprotection/peptide coupling protocols for solid phase peptide synthesis (SPPS) with 
Alloc-protected amines are well established.[30-31] As counterpart, the diester thiophene 4 
bears the C-terminal carboxylic acid in 2-position and a second ester in 4-position. The 
latter forms the maleimide core and is thus fixed as methyl ester, which in turn restricts the 
choice of the C-terminal protective group as transesterification occurs during condensation. 
In particular, using a C-terminal ethyl ester led to a mixture of the ethyl and methyl ester as 
the condensation product (cf. Scheme A1 in the appendix). Consequently, we favoured the 
methyl ester as protecting group for the C-terminal carboxylic acid.  
 
Scheme 7. Perkin condensation of the N-terminal precursor 3 and C-terminal precursor 4 to access 
the dithienylmaleimide 2. 
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Scheme 8: Synthetic route for the preparation of the N-terminal precursor 3. 
The synthetic pathway to access the N-terminal precursor 3 is depicted in Scheme 8. To 
prepare the thiophene nitrile 7 bromination of 2-methyl thiophene 5 and subsequent 
Rosenmund-von Braun reaction were performed according to literature procedures.[32-33] 
Thereafter, reduction of the nitrile with lithium aluminium hydride followed by immediate 
protection with allyl chloroformate afforded carbamate 8 in good yield (66% for 2 steps). 
Using Fmoc chloride instead led to the respective Fmoc derivative, which was not only less 
efficient (38% yield) but also caused the formation of side products in the following Friedel-
Crafts acylation. In particular, we observed simultaneous acylation of the Fmoc fluorene 
system (cf. Scheme A2 in the appendix). Even though the Alloc group should not be as prone 
to acylation, the Friedel-Crafts acylation was still the most challenging step of the synthesis. 
We noticed that the yield of glyoxylester 9 critically depends on the sequence of the addition 
of reagents. Best results (49%) were obtained by mixing 8 and methyl chlorooxoacetate 
prior to adding aluminium chloride slowly in small portions. Otherwise, the allyl carbamate 
was cleaved and the resulting primary amine was competitively acylated yielding compound 
10 as main product (Figure 21). Additionally, quenching the reaction with saturated sodium 
hydrogen carbonate solution instead of neutral water suppressed the formation of 
compound 11 which is obtained by addition of hydrochloric acid to the allyl double bond 
(Figure 21). Obviously, the allyl carbamate is not as robust as expected towards the present 
acidic conditions.  
 
Figure 21: Undesired side products of the acylation reaction of carbamate 8. 
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The use of zinc(II) chloride or iron(III) chloride as milder Lewis acids did not afford the 
desired product. Finally, aminolysis with aqueous ammonia converted the glyoxylester 9 
into the desired N-terminal precursor 3 in 92% yield. All in all, we achieved moderate to 
high yields (49 to 92%) for the particular synthesis towards 3 resulting in an overall yield of 
22% for six steps. 
 
Scheme 9. Synthesis of the C-terminal precursor 4. 
The C-terminal precursor 4 was prepared by esterification of the methyl thiophene acid 12 
in presence of thionyl chloride followed by Friedel-Crafts acylation and final thallium 
trinitrate mediated oxidative rearrangement (Scheme 9).[34-35] All intermediates could be 
isolated in good to excellent yields (77 to 97%) with an overall yield of 68% for three steps. 
It is noteworthy that initial yields of around 40% for the Friedel-Crafts acylation 
significantly increased to 77% after removal of stabilizers and reactive decomposition 
products from the solvent chloroform prior to drying and distillation (cf. Experimental 
Section). 
The N-terminal precursor 3 and the C-terminal precursor 4 were combined by Perkin 
condensation (Scheme 7). In order to provide a photochromic amino acid with a free 
carboxylic group ready for SPPS, the methyl ester of 2 was cleaved (Scheme 10). Non-
hydrolytic ester cleavage was required to avoid maleimide hydrolysis (cf. Scheme A4 in the 
appendix), which was achieved using lithium iodide in a polar aprotic solvent.[36] The SN2 
fashion C-O bond cleavage is based on the coordination of the lithium cation as hard acid at 
the oxygen atom (pulling factor) and the nucleophilic attack of the soft iodide at the carbon 
atom (pushing factor).[37] A large excess of lithium iodide and reflux conditions were 
necessary to achieve moderate conversion. The yield significantly changed with the solvent 
(Table 6). Best results (35%) could be achieved in acetone, whereas the reaction mixture 
mainly consisted of starting material in most other solvents. A more efficient deprotection 
protocol needs to be developed. 
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Table 6. Non-hydrolytic methyl ester deprotection of 2. 
Entry eq. LiI Solvent T [°C] Isolated yield[a] [%] 
1 3.0 EtOAc r.t. -- 
2 3.0 EtOAc reflux -- 
3 30 EtOAc reflux 26 
4 3.0 acetone reflux -- 
5 30 acetone reflux 35 
6 30 MeCN reflux -- 
7 30 DMSO 100 -- 
[a] If conversion was too low the product 1 was not isolated. 
 
5.2.2 Peptide Coupling 
 
 
Scheme 10. Non-hydrolytic cleavage of the methyl ester 2 and subsequent solid phase peptide 
synthesis to access the photochromic tripeptide 17. 
To explore the applicability of the title compound 1 in SPPS, we used Wang resin bound 
alanine and attached it by standard coupling protocol (Scheme 10). Subsequently, the Alloc 
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protecting group was catalytically removed through coordination to palladium(0) and 
nucleophilic attack of DABCO as allyl scavenger.[30] After another coupling/deprotection 
step with Fmoc alanine, the photochromic tripeptide 17 was released from the resin 
(Scheme 10) and identified by mass spectrometry. Currently, purification and complete 
characterization of 17 is in progress. 
 
5.2.3 Photochromism 
The dithienylmaleimide core structure can reversibly be toggled between a ring-open and 
ring-closed photoisomer (Figure 19). The photochemical properties of compounds 1 and 2 
were spectrophotometrically investigated. It is known that diarylmaleimides are not able to 
undergo photoisomerization in polar solvents due to a twisted intramolecular charge 
transfer (TICT).[38-39] However, the DTEs 1 and 2 showed excellent photochromic behavior 
in highly polar methanol (Figure 22 and Figure A4 in the appendix), which is in good 
accordance with the performance of other recently developed dithienylmaleimide 
derivatives.[21] This phenomenon can be explained by inductive and resonance effects of the 
substitution pattern on the aryl moieties.  
  
Figure 22: UV/Vis absorption spectra evolution of the dithienylmaleimide amino acid 1 (50 µM in 
MeOH) upon irradiation with 312 nm light; arrows indicate the changes of the absorption maxima 
with irradiation periods of 6 s. 
Upon irradiating a methanol solution of the ring-open form of compound 1 with UV light 
(312 nm), the absorption band at 250 nm immediately decreases. Simultaneously, new 
absorption maxima at 232 nm, 378 nm and 550 nm arise causing the color change from 
colorless to purple (Figure 22). Compared to the common DTE-cyclopentenes the 
absorption maxima are red shifted by approximately 25 nm.[11] The photostationary state 
was reached after 36 s of irradiation and the open form can be reobtained by irradiation 
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with visible light (> 420 nm) for 5 min. The photoswitchable amino acid 1 is stable over 
several closing/opening cycles (see Figure 23). 
 
Figure 23: Cycle performance of the dithienylmaleimide amino acid 1 (50 µM in MeOH). Changes 
in absorption at 554 nm were measured during an alternated irradiation with 312 nm light for 60 s 
and greater than 420 nm light for 5 min. 
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5.3 Conclusion 
We have developed an efficient synthesis of a photochromic dithienylmaleimide amino acid. 
The compound shows an increased hydrophilicity and water solubility compared to DTEs 
bearing a perfluorocyclopentene unit. Its absorption is bathochromically shifted and the 
irradiation with light of 312 nm and greater than 420 nm converts the open and closed 
photoisomers completely. As a protected amino acid the compound can conveniently be 
conjugated to biological molecules or incorporated in peptides by solid phase synthesis, as 
exemplarily demonstrated by coupling to alanine at the amino and carboxy function. 
Applications of the dithienylmaleimide amino acid in the photoregulation of peptide 
conformations or interactions can be envisaged.  
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5.4 Experimental Section 
5.4.1 General 
Commercial reagents and starting materials were purchased from Acros Organics, Alpha-
Aesar, Fluka, Sigma Aldrich or VWR and used without further purification. Solvents were 
used in p.a. quality and dried according to common procedures, if necessary. To purify the 
chloroform for Friedel-Crafts acylations, it was extracted with sulfuric acid (1 M), dried over 
calcium chloride, filtered through silica, subsequently refluxed with phosphorous pentoxide 
(5 – 10 g/L) and distilled under nitrogen atmosphere. Thienyl nitrile 7 and thienyl methyl 
ester 13 were prepared according to previously reported procedures.[33-34] Flash column 
chromatography was performed on a Biotage Isolera One automated flash purification 
system with UV/Vis detector using Sigma Aldrich MN silica gel 60 M (40-63 µm, 230-400 
grain diameter) for normal phase or pre-packed Biotage SNAP cartridges (KP-C18-HS) for 
reversed phase chromatography. Reaction monitoring via TLC was performed on alumina 
plates coated with silica gel (Merck silica gel 60 F254, 0.2 mm). Melting points were 
determined using a Stanford Research Systems OptiMelt MPA 100. NMR spectra were 
recorded on Bruker Avance 300 (1H 300.13 MHz, 13C 75.48 MHz) and Bruker Avance 400 
(1H 400.13 MHz, 13C 100.61 MHz) instruments. The spectra are referenced against the NMR-
solvent, chemical shifts δ are reported in ppm and coupling constants J are given in Hz. 
Resonance multiplicity is abbreviated as: s (singlet), d (doublet), t (triplet), m (multiplet) 
and b (broad). Carbon NMR signals are reported using DEPT 135 spectra with (+) for 
primary/tertiary, (−) for secondary and (q) for quaternary carbons. Mass spectra were 
recorded on Finnigan MAT95 (EI-MS), Agilent Q-TOF 6540 UHD (ESI-MS, APCI-MS), 
Finnigan MAT SSQ 710 A (EI-MS, CI-MS) or ThermoQuest Finnigan TSQ 7000 (ES-MS, APCI-
MS) spectrometer. UV/Vis absorption spectroscopy was performed using a Varian Cary BIO 
50 UV/Vis/NIR spectrometer. IR-spectra were recorded with a Specac Golden Gate Diamond 
Single Reflection ATR System in a Bio-Rad FT-IR-Spectrometer Excalibur FTS 3000. Signal 
intensity is abbreviated with s = strong, m = medium and w = weak. Standard hand-held 
lamps (Herolab, 312 nm, 6 W) were used for visualizing TLC plates and to carry out the ring-
closure reactions at 312 nm. The ring-opening reactions were performed with the light of a 
200 W tungsten light bulb which was passed through a 420 nm cut-off filter to eliminate 
higher energy light. The power of the light is given based on the specifications supplied by 
the company when the lamps were purchased. A light detector was not used to measure the 
intensity during the irradiation experiments. 
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5.4.2 New Compounds 
 
4-(4-(5-((((Allyloxy)carbonyl)amino)methyl)-2-methylthiophen-3-yl)-2,5-dioxo-2,5-
dihydro-1H-pyrrol-3-yl)-5-methylthiophene-2-carboxylic acid (1): Compound 2 
(40 mg, 0.09 mmol, 1.0 eq.) was dissolved in acetone (10 mL) and LiI (350 mg, 2.60 mmol, 
30 eq.) was added. The mixture was heated to 100 °C overnight. After cooling to room 
temperature it was quenched with 1 M HCl (5 mL) and diluted with CH2Cl2 (5 mL). The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic phases were dried over sodium sulfate and the solvent was removed at 
the rotary evaporator. Automated reversed phase flash column chromatography 
(MeCN/H2O with 0.05% TFA, 3 - 100% MeCN) yielded compound 1 (14 mg, 0.03 mmol, 
35%) as yellow foam; Rf: 0.04 (PE/EtOAc : 1/1); 1H-NMR (300 MHz, CD3CN): δ = 1.93 (3H, 
s, thiophene-CH3), 1.97 (3H, s, thiophene-CH3), 4.33 (2H, d, J = 6.3 Hz, thiophene-CH2NH), 
4.52 (2H, d, J = 5.3 Hz, CH2=CHCH2O), 5.18 (1H, dd, J = 10.5, 1.4 Hz, CH2=CHCH2), 5.27 (1H, 
dd, J = 17.3, 1.6 Hz, CH2=CHCH2), 5.74 – 6.05 (1H, m, CH2=CHCH2), 6.14 (1H, bs, CH2NHCO), 
6.79 (1H, s, thiophene-H), 7.60 (1H, s, thiophene-H), 8.80 (1H, bs, COOH); 13C-NMR (75 MHz, 
CD3CN): δ = 14.7 (+), 15.1 (+), 40.0 (−), 65.9 (−), 117.4 (−), 127.2 (q), 127.4 (+), 129.0 (q), 
131.3 (q), 134.0 (q), 134.3 (+), 136.0 (+), 136.1 (q), 141.1 (q), 141.7 (q), 149.5 (q), 157.0 (q), 
162.8 (q), 171.5 (q); IR  ̃ [cm-1]: 2926 (w), 1981 (w), 1769 (w), 1709 (s), 1544 (m), 
1459 (m), 1344 (m), 1246 (m), 1185 (m), 1150 (m), 1049 (w), 991 (m), 849 (w), 762 (m); 
UV/Vis (50 µM in MeOH): open isomer: max = 250 nm; closed isomer: max = 232 nm, 
378 nm, 550 nm; MS (ESI): m/z (%) = 346.0 (100, [M-AllocNH]+), 447.1 (60, MH+); HR-MS 
(ESI): calcd. for C20H18N2O6S2 (M+H)+, m/z = 447.0679; found 447.0676. 
 
Methyl 4-(4-(5-((((allyloxy)carbonyl)amino)methyl)-2-methyl-thiophen-3-yl)-2,5-
dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-methylthiophene-2-carboxylate (2): KOtBu (1 M 
in THF, 0.12 mL, 0.12 mmol, 1.2 eq.) was added to a solution of glyoxylamide 3 (28 mg, 
0.10 mmol, 1.0 eq.) in dry THF (1 mL) at 0 °C under nitrogen atmosphere. After stirring for 
90 min at 0 °C, diester 4 (27 mg, 0.12 mmol, 1.2 eq.) in THF (0.5 mL) was added at 0 °C and 
stirred for 24 h at room temperature. Then the reaction was heated to reflux for 1 h, 
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quenched with 1 M HCl solution (3 mL) and diluted with EtOAc (5 mL). The organic phase 
was washed with water (2 x 5 mL), brine (5 mL) and dried over MgSO4. The solvent was 
removed under reduced pressure and purification of the crude product by automated 
reversed phase flash column chromatography (H2O/EtOH, 20% - 45% EtOH) yielded 2 
(53 mg, 0.05 mmol, 50%) as yellow foam; Rf: 0.20 (PE/EtOAc : 2/1); 1H-NMR (400 MHz, 
CDCl3): δ = 1.90 (3H, s, thiophene-CH3); 1.98 (3H, s, thiophene-CH3), 3.87 (1H, s, OCH3), 4.45 
(2H, d, J = 6.0 Hz, thiophene-CH2NH), 4.60 (2H, d, J = 4.9 Hz, CH2=CHCH2O), 5.13 – 5.27 (2H, 
m, CH2=CHCH2 and CH2NHCO), 5.31 (1H, dd, J = 17.2, 1.2 Hz, CH2=CHCH2), 5.92 (1H, ddt, 
J = 16.2, 10.8, 5.5 Hz, CH2=CHCH2), 6.90 (1H, s, thiophene-H), 7.74 (1H, s, thiophene-H), 8.30 
(1H, bs, CONHCO); 13C-NMR (101 MHz, CDCl3): δ = 15.0 (+), 15.3 (+), 39.9 (−), 52.3 (+), 
65.9 (−), 117.9 (−), 125.8 (q), 126.7 (+), 127.5 (q), 130.9 (q), 132.7 (+), 134.8 (q), 134.9 (+), 
139.4 (q), 142.1 (q), 148.6 (q), 156.0 (q), 162.1 (q), 170.0 (q), 170.2 (q); IR  ̃ [cm-1]: 
3289 (w), 3070 (w), 2952 (w), 1703 (s), 1540 (m), 1458 (w), 1339 (m), 1248 (m), 994 (w), 
909 (m), 727 (m); UV/Vis (50 µM in MeOH): open isomer: max = 250 nm; closed isomer: 
max = 232 nm, 378 nm, 550 nm; MS (ESI): m/z (%) = 461.1 (100, MH+), 360.0 (98, 
[M-AllocNH]+), 483.1 (26), 519.1 (25), 462.1 (24), 571.3 (21), 361.0 (21), 270.1 (21); HR-MS 
(ESI): calcd. for C21H21N2O6S2 (M+H)+, m/z = 461.0838; found 461.0386. 
 
Allyl ((4-(2-amino-2-oxoacetyl)-5-methylthiophen-2-yl)methyl) carbamate (3): To a 
solution of oxoacetate 9 (282 mg, 0.95 mmol, 1.0 eq.) in THF (5 mL) was added a NH4OH 
solution (32% in H2O) (1.18 mL, 9.50 mmol, 10.0 eq.) at 0 °C. The reaction was stirred for 
90 min at room temperature and then quenched with water (5 mL). The aqueous phase was 
extracted with EtOAc (3 x 10 mL). The combined organic phases were dried over MgSO4 and 
the solvent was removed under reduced pressure. Compound 3 (253 mg, 0.90 mmol, 94%) 
was obtained as yellow solid and used without further purification; Rf: 0.21 
(PE/EtOAc : 1/1); m.p.: 108 °C; 1H-NMR (400 MHz, CDCl3): δ = 2.70 (3H, s, thiophene-CH3), 
4.44 (2H, d, J = 6.1 Hz, thiophene-CH2NH), 4.59 (2H, d, J = 5.1 Hz, CH2=CHCH2O), 5.21 (1H, d, 
J = 10.4 Hz, CH2=CHCH2), 5.24 – 5.43 (2H, m, CH2=CHCH2 and NH), 5.90 (1H, ddt, J = 16.2, 
10.7, 5.5 Hz, CH2=CHCH2), 6.05 (1H, bs, NH2), 7.06 (1H, bs, NH2), 7.86 (1H, s, thiophene-H); 
13C-NMR (101 MHz, CDCl3): δ = 16.7 (+), 39.8 (−), 65.9 (−), 117.9 (−), 129.0 (+), 130.8 (q), 
132.7 (+), 137.0 (q), 155.7 (q), 156.1 (q), 164.4 (q), 182.1 (q); IR  ̃ [cm-1]: 3402 (m), 
3301 (m), 3167 (w), 2962 (w), 1750 (m), 1686 (s), 1649 (s), 1535 (m), 1460 (m), 1254 (m), 
1047 (m), 796 (m); MS (ESI): m/z (%) = 300.1 (100, MNH4+), 283.1 (60, MH+),182 (30) 
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588.1 (27, 2MNa+); HR-MS (ESI): calcd. for C12H18N3O4S (M+NH4)+, m/z = 300.1013; found 
300.1012. 
 
Methyl 4-(2-methoxy-2-oxoethyl)-5-methylthiophene-2-carboxylate (4): Thallium 
trinitrate (850 mg, 1.91 mmol, 1.2 eq.) and 70% HClO4 (0.30 mL) were added to a 
suspension of 14 (316 mg, 1.59 mmol, 1.0 eq.) in MeOH (3 mL) at room temperature. After 
stirring for 24 h the mixture was concentrated under vacuum and diluted with water 
(5 mL). The aqueous phase was diluted with EtOAc (5 mL), extracted with EtOAc (3 x 5 mL) 
and dried over MgSO4. The solvent was evaporated and purification of the crude product by 
automated flash column chromatography (PE/EtOAc, 3% - 15% EtOAc) yielded compound 4 
(331 mg, 1.45 mmol, 91%) as colorless oil; Rf: 0.34 (PE/EtOAc : 5/1); 1H-NMR (300 MHz, 
CDCl3): δ = 2.43 (3H, s, thiophene-CH3), 3.54 (2H, s, thiophene-CH2C(O)OCH3), 3.70 (3H, s, 
thiophene-CH2C(O)OCH3), 3.85 (3H, s, C(O)OCH3), 7.61 (1H, s, thiophene-H); 13C-NMR 
(75 MHz, CDCl3): δ = 13.8 (+), 33.8 (−), 52.0 (+), 52.1 (+), 129.0 (q), 130.7 (q), 135.6 (+), 
144.0 (q), 162.6 (q), 170.9 (q); IR  ̃ [cm-1]: 2997 (w), 2953 (m), 2845 (w), 1736 (w), 
1704 (s), 1535 (w), 1457 (s), 1392 (w), 1331 (w), 1291 (m), 1250 (s), 1194 (s), 1132 (w), 
1063 (s), 1006 (m), 927 (w), 874 (w), 785 (w), 751 (s); MS (APCI): m/z (%) = 229.1 (100, 
MH+); HR-MS (APCI): calcd. for C10H12O4S (M+H)+, m/z = 229.0529; found 229.0531. 
 
 
Allyl ((5-methylthiophen-2-yl)methyl)carbamate (8): LAH (2.78 g, 73.2 mmol, 1.0 eq.) 
was added in portions to a solution of nitrile 7 (3.01 g, 24.4 mmol, 3.0 eq.) in dry Et2O 
(250 mL) at 0 °C under nitrogen atmosphere. After stirring for 4 h at room temperature the 
reaction was quenched with water (80 mL) and saturated NaHCO3 solution (50 mL) at 0 °C. 
The suspension was filtered and the aqueous phase was extracted with Et2O (3 x 80 mL). 
The combined organic phases were dried over MgSO4 and concentrated in vacuo. Then the 
residue was dissolved in dry THF (100 mL) and pyridine (2.47 mL, 30.50 mmol, 1.25 eq.) 
was added at 0 °C. Within 1 h allyl chloroformate (4.02 mL, 37.82 mmol, 1.55 eq.) in dry THF 
(5 mL) was dropped to the solution via a syringe pump at 0 °C. After stirring for 14 h at 
room temperature the reaction was quenched cautiously with water (50 mL) and extracted 
with EtOAc (3 x 30 mL). The combined organic phases were dried over MgSO4 and the 
solvent was removed under reduced pressure. Purification of the crude product by 
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automated flash column chromatography (PE/EtOAc, 8% - 15% EtOAc) yielded 8 (3.40 g, 
16.1 mmol, 66%) as yellow oil; Rf: 0.20 (PE/EtOAc : 9/1); 1H-NMR (400 MHz, CDCl3): δ = 
2.44 (3H, s, thiophene-CH3), 4.44 (2H, d, J = 5.7 Hz, thiophene-CH2NH), 4.59 (2H, d, J = 5.1 Hz, 
CH2=CHCH2O), 5.05 (1H, bs, NH), 5.21 (1H, d, J = 10.4 Hz, CH2=CHCH2), 5.30 (1H, d, 
J = 16.1 Hz, CH2=CHCH2), 5.92 (1H, ddt, J = 16.3, 10.8, 5.5 Hz, CH2=CHCH2), 6.57 (1H, dd, 
J = 3.2, 0.8 Hz, 4-thiophene-H), 6.74 (1H, d, J = 3.0 Hz, 3-thiophene-H); 13C-NMR (101 MHz, 
CDCl3): δ = 15.4 (+), 40.1 (−), 65.6 (−), 117.8 (−), 124.8 (+), 125.7 (+), 132.8 (+), 138.8 (q), 
139.9 (q), 155.9 (q); IR  ̃ [cm-1]: 3335 (m), 3073 (w), 2922 (w), 1695 (s), 1514 (m), 
1426 (w), 1236 (s), 982 (m), 799 (m); MS (ESI): m/z (%) = 212.1 (100, MH+), 151.1 (48), 
114.1 (47), 111.0 (35), 234.1 (27, MNa+); HR-MS (ESI): calcd. for C10H14NO2S (M+H)+, m/z = 
212.0740; found 212.0740. 
 
Methyl 2-(5-((((allyloxy)carbonyl)amino)methyl)-2-methylthiophen-3-yl)-2-
oxoacetate (9): Carbamate 8 (169 mg, 0.80 mmol, 1.0 eq.) and methyl chlorooxoacetate 
(81 µL, 0.88 mmol, 1.1 eq.) were dissolved in dry CH2Cl2 (6 mL) under nitrogen atmosphere. 
Then aluminium chloride (427 mg, 3.20 mmol, 4.0 eq.) was added in portions at 0 °C and the 
suspension was stirred for 20 h at room temperature. The reaction was quenched with 
saturated NaHCO3 solution (1 mL) at 0 °C and diluted with water (5 mL). The aqueous phase 
was extracted with CH2Cl2 (3 x 5 mL), the combined organic layers were washed with brine 
(10 mL) and dried over MgSO4. After evaporation of the solvent the crude product was 
purified by automated flash column chromatography (PE/EtOAc, 15% - 40% EtOAc) to 
obtain 9 (117 mg, 0.39 mmol, 49%) as brown oil; Rf: 0.22 (PE/EtOAc : 3/1); 1H-NMR 
(400 MHz, CDCl3): δ = 2.70 (3H, s, thiophene-CH3) 3.91 (3H, s, OCH3), 4.42 (2H, d, J = 6.1 Hz, 
thiophene-CH2NH), 4.58 (2H, d, J = 5.3 Hz, CH2=CHCH2O), 5.16 – 5.34 (3H, m, CH2=CHCH2 
and NH), 5.90 (1H, ddt, J = 16.3, 10.8, 5.6 Hz, CH2=CHCH2), 7.32 (1H, s, thiophene-H); 
13C-NMR (101 MHz, CDCl3): δ = 16.3 (+), 39.7 (−), 52.8 (+), 65.9 (−), 118.0 (−), 127.5 (+), 
131.0 (q), 132.6 (+), 138.0 (q), 154.8 (q), 156.1 (q), 164.0 (q), 180.0 (q); IR  ̃ [cm-1]: 
3395 (m), 2954 (w), 1726 (s), 1670 (s), 1517 (m), 1434 (m), 1242 (s), 1200 (s), 1112 (s), 
984 (m), 757 (m); MS (ESI): m/z (%) = 298.1 (100, MH+), 315.1 (58, MNH4+), 320.1 (48, 
MNa+), 185.0 (37); HR-MS (ESI): calcd. for C13H16NO5S (M+H)+, m/z = 298.0744; found 
298.0744. 
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Methyl 4-acetyl-5-methylthiophene-2-carboxylate (14): Thiophene 13 (800 mg, 
5.12 mmol, 1.0 eq.) and acetyl chloride (550 µL, 7.68 mmol, 1.5 eq.) were dissolved in 
purified anhydrous CHCl3 (10 mL) under nitrogen atmosphere. After cooling to 0 °C 
aluminium chloride (2.05 g, 15.4 mmol, 3.0 eq.) was added in small portions. The yellow 
suspension was heated to 45 °C overnight upon turning bright red, then the reaction was 
quenched with ice/water and the aqueous phase was extracted with ethyl acetate 
(3 x 10 mL). The combined organic phases were washed with a saturated solution of 
NaHCO3 (10 mL) and brine (10 mL). The organic phase was dried over MgSO4 and the 
solvent was evaporated. The crude product was purified by automated flash column 
chromatography (PE/EtOAc, 5% - 25% EtOAc) and 14 (781 mg, 3.94 mmol, 77%) was 
obtained as colorless solid; Rf: 0.41 (PE/EtOAc : 3/1); m.p.: 84 °C; 1H-NMR (300 MHz, 
CDCl3): δ = 2.52 (3H, s, thiophene-CH3), 2.76 (3H, s, acetyl-CH3), 3.88 (3H, s, OCH3), 8.03 (1H, 
s, thiophene-H); 13C-NMR (75 MHz, CDCl3): δ = 16.8 (+), 29.6 (+), 52.3 (+),128.5 (q), 
135.0 (+), 136.3 (q), 155.8 (q), 162.0 (q), 193.7 (q); IR  ̃ [cm-1]: 3007 (w), 2957 (w), 
1717 (s), 1678 (s), 1539 (s), 1457 (m), 1439 (m), 1254 (s), 1233 (s), 1074 (m), 1021 (w), 
745 (s); MS (EI): m/z (%) = 183.1 (100, [M-(CH3)]+), 198.1 (41, M+); HRMS (APCI): 
m/z (%) = 199.0 (100, MH+);  calcd. for C9H10O3S (M+H)+, m/z = 199.0423; found 199.0424. 
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5.4.3 Solid Phase Peptide Synthesis 
Solid phase peptide synthesis was carried out manually on 50 mg Wang resin (loading 1.0 – 
1.2 mmol) using the Fmoc strategy in BD Discardit II syringes (Becton Dickinson GmbH). 
Solvents and soluble reagents were removed by suction. A syringe was equipped with Wang 
resin (50 mg, 0.05 – 0.06 mmol) as solid phase, which was initially allowed to swell for 
60 min in DMF (3 mL). 
The amino acid coupling steps were performed in DMF (3 mL) with Fmoc-S-alanine (93 mg, 
0.30 mmol, 10 eq.), TBTU (94 mg, 0.29 mmol, 9.8 eq.), HOBt (46 mg, 0.30 mmol, 10 eq.) and 
DIPEA (11 µL, 0.60 mmol, 20 eq.). After shaking for 90 min another portion of TBTU (62 mg, 
0.19 mmol, 6.0 eq.) was added to complete the coupling step and the shaking was continued 
for further 30 min. The resin was washed with DMF/CH2Cl2/DMF (4 x 3 mL each) and the 
coupling step was repeated. 
Fmoc removal followed with piperidine/DMF (4:6, 3 mL) for 5 min, washing with DMF (2 x 
3 mL) and further 5 min of piperidine/DMF (2:8, 3 mL). After completion, the resin was 
washed with DMF/CH2Cl2/MeOH/DMF (4 x 3 mL each). 
The dithienylmaleimide amino acid 1 (13 mg, 0.03 mmol, 1.0 eq.) was attached to Wang-Ala-
NH2 15 (0.05 – 0.06 mmol, 1.7 – 2.0 eq.) by dissolving in DMF (2 mL) and adding TBTU 
(9 mg, 0.03 mmol, 1.0 eq.), HOBt (5 mg, 0.03 mmol, 1.0 eq) and DIPEA (10 µL, 0.06 mmol, 
2.0 eq.). After shaking for 90 min another portion of TBTU (6 mg, 0.02 mmol, 0.6 eq.) was 
added and the shaking continued for further 30 min. The resin was washed with 
DMF/CH2Cl2/DMF (4 x 3 mL each). 
Alloc was deprotected under nitrogen atmosphere using Pd(PPh3)4 (7 mg, 0.01 mmol, 
20 mol%) and DABCO (17 mg, 0.15 mmol, 5.0 eq.) in anhydrous CH2Cl2 (2.5 mL). After 
shaking for 90 min it was washed with CH2Cl2/DMF (5 x 3 mL each). 
Following the completion of the sequence the tripeptide 17 was released from the resin by 
treatment with TFA/CH2Cl2 (95:5, 1 mL) for 60 min. It was repeated and the solvent of the 
combined filtrates was removed by nitrogen purge. 
The tripeptide 17 was separated from byproducts by automated reversed phase flash 
column chromatography (MeCN/H2O with 0.05% TFA, 3-100% MeCN) and requires further 
purification by preparative HPLC.  
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5.4.4 Photochemical Investigations 
Photochemical syntheses of the ring-closed isomers. Solutions of compounds 1 and 2 in 
MeOH (50 µM) were irradiated with a 312 nm lamp until complete conversion (36 s) 
yielding pink solutions containing the ring-closed isomers. The changes in the UV/Vis 
absorption spectra are representatively shown for compound 1 in Figure 22 and for 
compound 2 in the appendix in Figure A4.  
Fatigue resistance studies. In order to test the robustness of the photochromic systems, 
photochemical cycling studies were recorded for the dithienylmaleimides 1 and 2 (see 
Figure 23 and appendix, Figure A4). In each case, a solution of the ring-open photoswitch in 
MeOH (50 µM) was alternately irradiated with 312 nm light for 60 s and with visible light 
>420 nm for 5 min over eight cycles. The absorption change at 565 nm was recorded after 
each cycle and plotted against the cycle number.  
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6.1 Introduction 
Maleic hydrazide is a well-established plant growth inhibitor that was first reported in 
1949.[1] Agriculture exploits its ability to prevent sprouting during growth or storage. It is 
usually applied on potatoes, onions and tobacco, or to prevent weed spread.[2-5] Even if its 
uptake and metabolization by mammalians has been investigated for decades, the impact on 
human health is still not fully examined and subject of ongoing research.[6-9] Maleic 
anhydride suppresses cell proliferation in plants by inhibiting their DNA and protein 
synthesis.[7] Moreover, its structural similarity with pyrimidine bases suggests intercalation 
into the DNA.[10]  
 
Figure 24. Tautomers of maleic hydrazide; diketo 1A, monolactim 1B and dihydroxy tautomer 1C. 
Analogous to nucleic bases, maleic hydrazide exhibits different tautomers appearing as 
diketo, monolactim or dihydroxy form (Figure 24). Experimental[10-11] and theoretical[12-14] 
studies indicate a predominance of the diketo 1A and the monolactim tautomer 1B as they 
seem similarly stable in solid state, solution and gas phase, whereas the dihydroxy form 1C 
is less populated.[14] NMR studies revealed that 1B is favored in polar solvents,[15] which is 
supported by the hypothesis that contiguous heteroatoms of the same hybridization type 
are strongly destabilizing.[16] Interestingly, new investigations on 2,3-diaryl-substituted 
maleic hydrazides report the exclusive formation of maleic hydrazide 1A without any 
monolactim byproduct.[17] Furthermore, it was recently shown, that UV irradiation 
generates the N-aminomaleimide tautomer 1D (Scheme 11).[18] 
 
Scheme 11. UV-induced unimolecular transformations of 1B into the N-aminomaleimide 1D.[18] 
In the course of exploring the reactivity of dithienylmaleimides, we discovered 
photochromic dithienyl maleic hydrazides as a new generation of DTE photoswitches. They 
comprise a six-membered core cycle, which is able to adopt different tautomeric structures 
as known for maleic hydrazide. We therefore wanted to investigate the interplay of 
photochromism and tautomerism of a dithienyl maleic hydrazide upon irradiation with UV 
and visible light. 
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6.2 Initial Results and Discussion 
To develop a new generation of photochromic dithienylethenes, we treated the bischloro 
dithienylmaleimide 1 with hydrazine under acidic conditions to afford the respective 
dithienyl maleic hydrazide 2 (Scheme 12).[19-20] We obtained two products that exhibited the 
same mass, in particular a photochromic blue fraction and a yellow fraction that was stable 
towards UV irradiation. The latter was not further investigated. According to the reported 
investigations on the diphenyl-substituted maleic hydrazide, the reaction product is 
estimated to appear as diketo form 2A.[17] This may be the case if the tautomerism 
equilibrium is dependent on the substitution at the 2- and 3-position of the maleic 
hydrazide. Else, the monolactim tautomer 2B is expected to be predominant as it is the 
preferred tautomer of maleic hydrazide.[15-16] 
 
Scheme 12. Synthesis of the dithienyl maleic hydrazide 2A and its tautomers 2B and 2C.[19] 
To get further insight into the proton distribution on the dithienyl maleic hydrazide 2, we 
applied NMR spectroscopy. Thereby, dimethylsulfoxide-d6 was used as aprotic polar solvent. 
The 1H-NMR spectra shows two separated broad singlets with the same intensity and high 
chemical shifts (11.14 and 12.24 ppm), thus indicating the existence of two different groups 
with hydrogen bonding ability (Figure 25).  
 
Figure 25. 1H-NMR spectra (10 to 13 ppm) of the dithienyl maleic hydrazide 2 in DMSO-d6. 
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In the case of a symmetric molecule as in 2A or 2C, only one signal is expected for both 
hydrazide protons. We could hence conclude that the title compound may mainly be present 
as tautomer 2B in a DMSO solution. Additionally, the thienyl and methyl protons appear as 
broad singlets, which may result from proton exchange implying the existence of a 
tautomerism equilibrium. Using methanol-d4 as polar protic solvent shows only the 
broadened signals for the methyl and thienyl protons, the resonance signals at 11 and 
12 ppm disappear.  
The physicochemical properties of the new dithienyl maleic hydrazide 2 were 
spectrophotometrically investigated by alternate irradiation with 312 nm or greater than 
420 nm light, respectively. Similar to known photochromic dithienylethenes, it can 
reversibly be toggled between two photoisomers (Scheme 13, upper reaction). Surprisingly, 
the color of the closed isomer of compound 2 in solution changed with the solvent, e.g. it 
appeared purple in methanol and blue in chloroform (Figure 26). The observed 
solvatochromism may be due to a solvent induced shift in the tautomerism equilibrium 
(Scheme 12). 
 
 
 
 
Figure 26. Coloration and decoloration of dithienyl maleic hydrazide 2 dissolved in methanol or 
chloroform upon irradiation with UV or visible light, respectively. The color is dependent on the 
solvent, appearing purple in methanol and blue in chloroform. 
Table 7. Absorption maxima of the closed isomer of compound 2 dependent on the solvent. 
Entry Solvent max [nm] 
1 MeOH 351, 560 
2 CHCl3 340, 592 
3 acetone 342, 551 
3 toluene[a] 362, 590, 612 
4 toluene[b] 323, 555, 612 
[a] up to 40 s of UV irradiation; [b] more than 40 s of UV irradiation. 
CHCl3 MeOH CHCl3 MeOH 
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Upon irradiating a solution of the ring-open form of compound 2 in the respective solvent 
with UV light (312 nm), new absorption maxima arise causing the color change (Figure 26 
and Figure 27). The position of this absorption band is strongly dependent on the solvent 
(Table 7). Compared to the common DTE-cyclopentenes the absorption maxima are red 
shifted by approximately 25 nm, which is in good accordance with the related 
dithienylmaleimdes (see Chapter 3).[21] The photostationary state was reached after 71 to 
90 s of irradiation. Particularly in toluene, we observed a maximum shift after 40 s of UV 
irradiation, which could be due to UV-light induced photoisomerization according to Reva et 
al. (Scheme 13).[18] The open form can be reobtained by irradiation with visible light 
(> 420 nm) for 10 min. 
 
Scheme 13. Possible UV-light induced reactions of 2B. 
 
Figure 27. Absorption spectra evolution of maleic hydrazide 2 (25 µM in MeOH or toluene) upon 
irradiation with 312 nm light; arrows indicate the changes of the absorption maxima with irradiation 
periods of 6 s. 
In contrast to the highly fatigue-resistant dithienylmaleimides (c.f. Chapter 3), the dithienyl 
maleic hydrazide 2 shows rather low photostability. It is almost completely degraded after 
eight iterations of alternate ring-closing/-opening cycles (Figure 28). 
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Figure 28. Cycle performance of maleic hydrazide 2. Changes in absorption at 565 nm were 
measured during an alternated irradiation the inhibitor solution (25 µM in MeOH) with 312 nm light 
for 60 s and greater than 420 nm light for 10 min. 
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6.3 Conclusion 
In summary, we discovered a new type of dithienylethenes. According to the present data it 
is presumably a dithienyl maleic hydrazide, which adopts its monolactim tautomer as 
preferred structure. Irradiation with UV or visible light, respectively, toggles the resulting 
compound reversibly between two photoisomers, whereby we observed a solvatochromism 
of the ring-closed form. However, it only exhibits rather low photostability compared to 
other dithienylethenes. To draw conclusions about the interplay of tautomerism, 
solvatochromism and photoisomerization, more detailed investigations are necessary, e.g. 
temperature-dependent 2D NMR measurements in different solvents before and after UV 
irradiation. Additionally, it would be interesting if the hydrazide moiety can be derivatized, 
thus establishing new possibilities to functionalize this new type of photoswitches. 
 
 
6.4 Experimental Section 
 
4,5-Bis(5-chloro-2-methylthiophene-3-yl) maleic hydrazide (2). Hydrazine 
monohydrate (16 µL, 0.34 mmol, 1.2 eq.) was dissolved in MeOH/THF (5:1, 12 mL) and 
cooled to 0 °C. Fuming hydrochloric acid (0.1 mL) was added dropwise, after which the bath 
was removed and dithienylmaleimide 1 (100 mg, 0.28 mmol, 1.0 eq.) was added. It was 
refluxed for 24 h. After cooling to r.t. it was extracted with ethyl acetate (2 x 10 mL), dried 
over magnesium sulfate and the volatiles removed. The crude product was obtained as 
yellow powder and purification by automated column chromatography (PE/EtOAc, 30% –
60% EtOAc) yielded 31 mg (0.08 mmol, 30%) of 2B as blue powder. 1H-NMR (300 MHz, 
MeOD): δ = 2.09 (6H, bs, 2 thiophene-CH3), 6.54 (1H, bs, thiophene-H), 6.62 (1H, bs, 
thiophene-H); 1H-NMR (400 MHz, DMSO): δ = 2.11 – 1.92 (6.3 H, m, 2 thiophene-CH3), 2.17 
(0.3H, s), 6.70 (2.1H, bm, 2 thiophene-H), 7.40 (0.1 H, s), 11.14 (1H, bs), 12.24 (1H, bs); 
MS (ESI): m/z (%) = 373.0 (100, [MH+]), 375.0 (70, [MH+]). 
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7.1 Supplementary NMR spectra for Chapter 1 
1H-NMR for compound 2: 
 
13C-NMR for compound 2: 
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1H-NMR for compound 3:  
 
13C-NMR for compound 3: 
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1H-NMR for compound 4: 
 
13C-NMR for compound 4: 
 
  
Appendix 
   
 
 94 
1H-NMR for compound 5:  
 
13C-NMR for compound 5: 
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1H-NMR for compound 6: 
 
13C-NMR for compound 6: 
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1H-NMR for compound 7:  
 
13C-NMR for compound 7: 
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1H-NMR for compound 10: 
 
13C-NMR for compound 10: 
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1H-NMR for compound 11: 
 
13C-NMR for compound 11: 
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1H-NMR for compound 12:  
 
13C-NMR for compound 12: 
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1H-NMR for compound 13:  
 
13C-NMR for compound 13: 
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7.2 Supporting Information for Chapter 2 
7.2.1 Supplementary Figures 
 
Figure A1. UV/Vis absorption spectra evolution of DTEs 1-3 and 5-7 (50 µM in MeOH) upon irradiation 
with 312 nm light; arrows indicate the changes of the absorption maxima with irradiation periods of 
6 s; the colors of the respective solutions are depicted. 
 
 
 
Figure A2. Cycle performances of compounds 1-3 and 5-7. Changes in absorption at 525 nm were 
measured during an alternated irradiation the inhibitor solution (50 µM in MeOH) with 312 nm light 
for 60 s and greater than 420 nm light for 15 min. 
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Figure A3. Dose-response curves for DTEs 1-3 and 5-7 in their open (blue) and closed (red) 
photoisomers with FR180204 as reference.  
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7.2.2 Supplementary NMR spectra 
1H-NMR for compound 2:  
 
13C-NMR for compound 2:  
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1H-NMR for compound 3: 
 
 
13C-NMR for compound 3:  
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1H-NMR for compound 4: 
 
 
13C-NMR for compound 4:  
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1H-NMR for compound 6: 
 
 
13C-NMR for compound 6:  
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1H-NMR for compound 7: 
 
 
13C-NMR for compound 7:  
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7.3 Supporting Information for Chapter 3 
7.3.1 Supplementary Synthetic Data 
 
Scheme A1. Perkin condensation of the N-terminal precursor 3 and C-terminal precursor 4b to 
access the dithienylmaleimide 2 and 2b. 
 
Scheme A2. Synthesis of the N-terminal precursor 9b using Fmoc protection. Double acylated 9c 
occurred as main product. 
 
Scheme A3. Synthesis of the C-terminal ethyl ester precursor 4b. 
 
Scheme A4. Hydrolytic ester cleavage yielded the anhydride 1b. 
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4-(4-(5-((((Allyloxy)carbonyl)amino)methyl)-2-methylthiophen-3-yl)-2,5-dioxo-2,5-
dihydrofuran-3-yl)-5-methylthiophene-2-carboxylic acid (1b): A mixture of 2 and 2b 
(62 mg) in 10 mL of H2O/MeOH/THF (2:5:3, v/v/v) was stirred for 20 h with NaOH (78 mg, 
1.95 mmol) at room temperature. After addition of water (10 mL) the reaction mixture was 
washed with EtOAc (2 x 10 mL) and then acidified with conc. HCl to pH 1. The aqueous 
phase was extracted with EtOAc (3 x 10 mL) and the combined organic phases were dried 
over magnesium sulfate. Evaporation of the solvent and purification of the crude product by 
automated reversed phase flash column chromatography (H2O/MeCN, 20% - 55% MeCN) 
yielded 1b (29 mg, 0.06 mmol) as green solid; Rf: 0.02 (PE/EtOAc : 1/1); m.p.: 84 °C; 
1H-NMR (400 MHz, DMSO-d6): δ = 1.92 (3H, s, thiophene-CH3), 1.97 (3H, s, thiophene-CH3), 
4.28 (2H, d, J = 6.1 Hz, thiophene-CH2NH), 4.49 (2H, d, J = 5.3 Hz, CH2=CHCH2O), 5.18 (1H, dd, 
J = 10.5, 1.4 Hz, CH2=CHCH2), 5.27 (1H, dd, J = 17.2, 1.5 Hz, CH2=CHCH2), 5.90 (1H, ddt, 
J = 17.2, 10.6, 5.3 Hz, CH2=CHCH2), 6.87 (1H, s, thiophene-H), 7.65 (1H, s, thiophene-H), 7.90 
(1H, t, J = 6.0 Hz, CH2NHCO), 13.27 (1H, bs, COOH); 13C-NMR (75 MHz, DMSO-d6): δ = 
14.1 (+), 14.5 (+), 38.8 (−), 64.4 (−), 116.9 (−), 124.9 (q), 125.5 (+), 126.8 (q), 131.6 (q), 
133.5 (+), 133.9 (+), 135.6 (q), 140.8 (q), 141.4 (q), 148.6 (q), 155.9 (q), 162.2 (q), 164.9 (q), 
164.9 (q); IR  ̃ [cm-1]: 3327 (w), 3164 (w), 3020 (w), 2925 (m), 1764 (s), 1702 (m), 1541 
(m), 1458 (w), 1254 (m), 931 (m), 750 (w); UV/Vis (50 µM in MeOH): open isomer: 
max = 246 nm; closed isomer: max = 384 nm, 568 nm; MS (ESI): m/z (%) = 448.1 (100, 
MH+), 347.0 (98, [M-AllocNH]+); HR-MS (ESI): calcd. for C20H18NO7S2 (M+H)+, m/z = 
448.0519; found 448.0516. 
 
Ethyl/Methyl 4-(4-(5-((((allyloxy)carbonyl)amino)methyl)-2-methyl-thiophen-3-yl)-
2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-methylthiophene-2-carboxylate (2/2b).  
KOtBu (1 M in THF) (1.34 mL, 1.34 mmol, 1.2 eq.) was added to a solution of 3 (316 mg, 
1.12 mmol, 1.0 eq.) in dry THF (6 mL) at 0 °C under nitrogen atmosphere. After stirring for 
90 min at 0 °C, diester 4b (326 mg, 1.34 mmol, 1.2 eq.) was added at 0 °C and stirred for 
15 h at room temperature. Then the reaction was heated to 60 °C for 1 h, quenched with 1 M 
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HCl solution (4 mL) and diluted with EtOAc (10 mL). The organic phase was washed with 
water (3 x 5 mL), brine (5 mL) and dried over magnesium sulfate. The solvent was removed 
under reduced pressure and purification of the crude product by automated reversed phase 
flash column chromatography (H2O/EtOH, 20% - 45% EtOH) yielded 2b (40 mg, 0.08 mmol, 
8%) as orange foam, 2 (74 mg, 0.16 mmol, 14%) as yellow foam and a mixed fraction of both 
(65 mg); Analysis of 1b: Rf: 0.25 (PE/EtOAc : 2/1); 1H-NMR (400 MHz, CDCl3):  = 1.36 (3H, 
t, J = 7.1 Hz, O−CH2−CH3), 1.91 (3H, s, thiophene-CH3), 1.97 (3H, s, thiophene-CH3), 4.33 (2H, 
q, J = 7.1 Hz, O−CH2−CH3), 4.45 (2H, d, J = 5.9 Hz, C−CH2−NH), 4.60 (2H, d, J = 4.8 Hz, 
O−CH2−CH), 5.14 –5.26 (2H, m, CH2=CH−CH2 and CH2−NH−CO), 5.31 (1H, dd, J = 17.2, 1.1 Hz, 
CH2=CH−CH2), 5.92 (1H, ddt, J = 16.3, 10.8, 5.6 Hz, CH2=CH−CH2), 6.90 (1H, s, thiophene-H), 
7.75 (1H, s, thiophene-H), 7.97 (1H, bs, CO−NH−CO); 13C-NMR (101 MHz, CDCl3):  = 
14.3 (+), 15.0 (+), 15.3 (+), 39.9 (−), 61.4 (−), 65.9 (−), 117.9 (−), 125.8 (q), 126.7 (+), 
127.4 (q), 131.4 (q), 132.7 (+), 132.8 (q), 134.7 (+), 139.4 (q), 142.1 (q), 148.4 (q), 156.0 (q), 
161.7 (q), 170.0 (q), 170.1 (q); IR  ̃ [cm-1]: 3288 (w), 3071 (w), 2980 (w), 1710 (s), 
1541 (m), 1458 (w), 1252 (m), 995 (w), 916 (w), 760 (w); UV/Vis (50 µM in MeOH): open 
isomer: max = 250 nm; closed isomer: max = 232 nm, 378 nm, 554 nm; MS (ESI): m/z (%) = 
475.1 (100, MH+), 374.1 (78, [M-AllocNH]+), 476.1 (26), 533.2 (24, [MNH4 + MeCN]+), 
497.1 (21); HR-MS (ESI): calcd. for C22H23N2O6S2 (M+H)+, m/z = 475.0993; found 475.0992.  
 
Ethyl 4-(2-methoxy-2-oxoethyl)-5-methylthiophene-2-carboxylate (4b). Thallium tri-
nitrate (2.20 g, 4.94 mmol, 1.2 eq.) and 70% HClO4 (2 mL) were added to a suspension of 
14b (875 mg, 4.12 mmol, 1.0 eq.) in MeOH (20 mL) at room temperature. After stirring for 
24 h the mixture was concentrated under vacuum and diluted with water (5 mL). The 
aqueous phase was extracted with chloroform (3 x 5 mL) and dried over magnesium sulfate. 
The solvent was evaporated and purification of the crude product by automated flash 
column chromatography (PE/EtOAc, 3% - 15% EtOAc) yielded 816 mg (3.37 mmol, 82%) of 
compound 4b as yellowish oil; Rf: 0.23 (PE/EtOAc : 9/1); 1H-NMR (400 MHz, CDCl3):  = 
1.35 (3H, t, J = 7.1 Hz, O−CH2−CH3), 2.42 (3H, s, thiophene-CH3), 3.54 (2H, s, C−CH2−CO), 3.70 
(3H, s, CO−O−CH3), 4.31 (2H, q, J = 7.1 Hz, O−CH2−CH3), 7.60 (1H, s, thiophene-H); 13C-NMR 
(75 MHz, CDCl3):  = 13.8 (+), 14.4 (+), 33.8 (−), 52.2 (+), 61.0 (−), 129.6 (q), 130.6 (q), 
135.4 (+), 143.8 (q), 162.2 (q), 171.0 (q); IR  ̃ [cm-1]: 3081 (w), 2987 (w), 2922 (w), 
1730 (s), 1705 (s), 1460 (m), 1254 (s), 1201 (s), 1172 (s), 1061 (s); MS (EI): m/z (%) = 
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183.1 (100, [M-(CO2Me)]+), 242.1 (67, M+), 155.1 (61), 197.0 (49, [M-(EtO)]+), 182.1 (47); 
HR-MS (ESI): calcd. for C11H14NaO4S (M+Na)+, m/z = 265.0505; found 265.0502.  
 
 
(9H-Fluoren-9-yl)methyl ((5-methylthiophen-2-yl)methyl)carbamate (8b). To an ice-
bath cooled solution of nitrile 7 (2.00 g, 16.24 mmol, 1.0 eq) in anhydrous Et2O (200 mL), 
LAH (1.85 g, 48.71 mmol, 3.0 eq) was slowly added. After stirring for 2 h at room 
temperature the reaction mixture was quenched with water (6 mL). The precipitate was 
filtered off and the aqueous phase was extracted with Et2O (2 x 10 mL). 9-Fluorenylmethyl 
chloroformate (4.20 g, 16.24 mmol, 1.0 eq) was added to the combined organic phases and 
the reaction mixture was stirred at room temperature overnight. The solvent was removed 
under reduced pressure and the crude product was purified by automated flash column 
chromatography (PE/EtOAc, 5 - 25% EtOAc) affording 2.14 g (6.12 mmol, 38%) of 8b as 
beige solid. 1H-NMR (400 MHz, CDCl3): δ = 2.45 (3H, s, thiophene-CH3), 4.23 (1H, t, J = 
6.6 Hz, fluorenyl-H), 4.43 – 4.47 (4H, m, fluorenyl-CH2 and thiophene-CH2), 5.17 (1H, bs, 
Fmoc-NH), 6.59 (1H, bs, thiophene-H), 6.74 (1H, bs, thiophene-H), 7.31 (2H, t, J = 7.4 Hz, 
2 phenyl-H), 7.41 (2H, t, J = 7.4 Hz, 2 phenyl-H), 7.59 (2H, d, J = 7.4 Hz, 2 phenyl-H), 7.77 (2H, 
d, J = 7.6 Hz, 2 phenyl-H); 13C-NMR (100 MHz, CDCl3): δ = 15.4 (+), 40.2 (–), 47.3 (+), 
66.8  (–), 120.0 (+), 124.9 (+), 125.1 (+), 125.8 (+), 127.1 (+), 127.7 (+), 138.8 (q), 139.9 (q), 
141.4 (q), 143.9 (q), 156.1 (q); MS (ESI): m/z (%) = 350.1 (100, [MH+]), 372.1 (94, [MNa+]), 
721.1 (50, [2 MNa+]), 699.2 (37, [2 MH+]); HR-MS (ESI): calcd. for C21H20NO2S (MH+), m/z = 
350.1209; found 350.1206. 
 
Methyl-2-(5-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-2-methylthio-
phen-3-yl)-2-oxoacetate (9b/9c). In a crimp top vial a solution of methyl-
chlorooxoacetate (19 mg, 0.15 mmol, 1.1 eq) in anhydrous CH2Cl2 (2 mL) was added to AlCl3 
(75 mg, 0.56 mmol, 4.0 eq) under nitrogen atmosphere. It was cooled by ice-bath and a 
solution of 8b (50 mg, 0.14 mmol, 1.0 eq) in anhydrous CH2Cl2 (2 mL) was added dropwise 
via syringe. The reaction mixture was stirred for 2 h at 0 °C, and subsequently quenched by 
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addition of ice water (5 mL), which led to decoloration. The aqueous phase was extracted 
with CH2Cl2 (2 x 5 mL) and the combined organic phases were washed with saturated 
NaHCO3 and brine (each 5 mL) and dried over magnesium sulfate. Purification by flash 
chromatography (PE/EtOAc, 5-15% EtOAc) provided 22 mg (0.05 mmol, 36%) of 9b and 35 
mg (0.07 mmol, 45%) of 9c, both as slightly yellow oil. Analysis of 9b: 1H-NMR (400 MHz, 
CDCl3): δ = 2.72 (3H, s, thiophene-CH3), 3.93 (3H, s, oxoacetyl-OCH3), 4.23 (1H, t, J = 6.6 Hz, 
fluorenyl-H), 4.44 − 4.46 (4H, m, fluorenyl-CH2 and thiophene-CH2), 5.20 (1H, bs, Fmoc-NH), 
7.31 (2H, t, J = 7.4 Hz, 2 fluorenyl-H), 7.35 (1H, s, thiophene-H), 7.40 (2H, t, J = 7.3 Hz, 
2 fluorenyl-H), 7.58 (2H, d, J = 7.3 Hz, 2 fluorenyl-H), 7.76 (2H, d, J = 7.5 Hz, 2 fluorenyl-H); 
13C-NMR (100 MHz, CDCl3): δ = 16.3 (+), 39.7 (−), 47.2 (+), 52.8 (+), 67.0 (−), 120.0 (+), 
125.0 (+), 127.1 (+), 127.6 (+), 127.8 (+), 131.0 (q), 137.9 (q), 141.4 (q), 143.8 (q), 164.0 (q), 
179.9 (q); MS (ESI): m/z (%) = 436.1 (100, [MH+]); Analysis of 9c: 1H NMR (300 MHz, 
CDCl3): δ = 2.72 (3H, s, thiophene-CH3), 3.92 (3H, s, oxoacetyl-OCH3), 3.99 (3H, s, oxoacetyl-
OCH3), 4.38 – 4.24 (2H, m, CH2), 4.46 (2H, d, J = 5.9 Hz, CH2), 4.72 – 4.50 (1H, m, fluorenyl-H), 
5.30 (1H, bs, Fmoc-NH), 7.35 (1H, s, thiophene-H), 7.53 – 7.38 (2H, m, 2 fluorenyl-H), 7.62 
(1H, d, J = 7.4 Hz, fluorenyl-H), 7.85 (2 H, dd, J = 7.4, 3.8 Hz, 2 fluorenyl-H), 8.08 (1 H, dd, J = 
8.0, 1.4 Hz, fluorenyl-H), 8.28 (1H, s, fluorenyl-H); MS (ESI): m/z (%) = 522.1 (100, [MH+]), 
539.1 (63, [MNH4+]), 544.1 (36, [MNa+]). 
 
Ethyl 4-acetyl-5-methylthiophene-2-carboxylate (14b). A solution of acetyl chloride 
(128 µL, 1.80 mmol, 1.5 eq.) in dry chloroform (2 mL) was added to AlCl3 (480 mg, 
3.60 mmol, 3.0 eq.) at room temperature under nitrogen atmosphere. After stirring for 
10 min a solution of 13b (204 mg, 1.20 mmol, 1.0 eq.) in dry chloroform (2 mL) was 
dropped to the suspension. The mixture was heated to 60 °C for 9 h, then the reaction was 
quenched with ice/water and the aqueous phase was extracted with chloroform 
(2 x 30 mL). The combined organic phases were washed with a saturated solution of 
NaHCO3 (50 mL) and brine (50 mL). The organic phase was dried over magnesium sulfate 
and the solvent was evaporated. The crude product was purified by automated flash column 
chromatography (PE/EtOAc, 8% - 30% EtOAc) and 180 mg of 14b (180 mg, 0.85 mmol, 
71%) were obtained as colorless solid; Rf: 0.15 (PE/EtOAc : 9/1); m.p.: 103 °C; 1H-NMR 
(400 MHz, CDCl3):  = 1.37 (3H, t, J = 7.1 Hz, O−CH2−CH3), 2.52 (3H, s, thiophene-CH3), 2.75 
(3H, s, acetyl-CH3), 4.34 (2H, q, J = 7.1 Hz, O−CH2−CH3), 8.02 (1H, s, thiophene-H); 13C-NMR 
(101 MHz, CDCl3):  = 14.3 (+), 16.8 (+), 29.6 (+), 61.4 (−), 129.0 (q), 134.7 (+), 136.3 (q), 
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155.6 (q), 161.6 (q), 193.7 (q); IR  ̃ [cm-1]: 3008 (w), 2985 (w), 2944 (w), 1713 (s), 
1670 (s), 1540 (s), 1452 (m), 1250 (s), 1236 (s), 1082 (s), 1021 (w), 747 (s); MS (EI): 
m/z (%) = 197.0 (100, [M-(CH3)]+), 169.0 (70, [M-(COCH3)]+), 212.1 (63, M+), 167.1 (43), 
43.1 (27); HR-MS (ESI): calcd. for C10H13O3S (M+H)+, m/z = 213.0580; found 213.0581. 
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7.3.2 Supplementary Figures 
    
    
Figure A4. Upper spectra: UV/Vis absorption spectra evolution of the dithienylanhydride 1b (left) 
and the dithienylmaleimide 2 (right), each 50 µM in MeOH, upon irradiation with 312 nm light; 
arrows indicate the changes of the absorption maxima with irradiation periods of 6 s. Lower 
spectra: Cycle performance of the dithienylanhydride 1b (left) and dithienylmaleimide 2 (right). 
Changes in absorption at 556 nm were measured during an alternated irradiation with 312 nm light 
for 60 s and greater than 420 nm light for 5 min. 
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7.3.3 Supplementary NMR spectra 
1H-NMR for compound 1:  
 
13C-NMR for compound 1: 
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1H-NMR for compound 1b: 
 
13C-NMR for compound 1b: 
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1H-NMR for compound 2: 
 
13C-NMR for compound 2: 
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1H-NMR for compound 2b: 
 
13C-NMR for compound 2b: 
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1H-NMR for compound 3: 
 
13C-NMR for compound 3: 
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1H-NMR for compound 4: 
 
13C-NMR for compound 4: 
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1H-NMR for compound 8: 
 
13C-NMR for compound 8: 
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1H-NMR for compound 8b:  
 
13C-NMR for compound 8b: 
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1H-NMR for compound 9: 
 
13C-NMR for compound 9: 
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1H-NMR for compound 9b: 
 
13C-NMR for compound 9b: 
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1H-NMR of compound 9c:  
 
1H-NMR for compound 14: 
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13C-NMR for compound 14: 
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7.4 List of Abbreviations 
A   absorption 
AICAR   aminoimidazole carboxamide ribonucleotide 
Ala   alanine 
AlCl3   aluminium chloride 
Alloc   allyloxycarbonyl 
Alloc-Cl  allyl chloroformate 
APCI   atmospheric-pressure chemical ionization 
aq.   aqueous 
Ar   aryl 
ATP   adenosine triphosphate 
B(OMe)3  trimethyl borate 
BSA   bovine serum albumin 
calcd.   calculated 
CDCl3   deuterated chloroform 
CD3CN   deuterated acetonitrile 
CHCl3   chloroform 
CH2Cl2   dichloromethane 
CHO   Chinese hamster ovary cells 
CI   chemical ionization 
CuCN   copper(I) cyanide 
d   dublet 
d   distance 
δ   chemical shift 
DABCO   1,4-diazabicyclo[2.2.2]octane 
DAD   diode array detector 
DIPEA   N,N-diisopropylethylamine or Hünig’s base 
DMF   dimethylformamide 
DMSO   dimethyl sulfoxide 
DTE   1,2-dithienylethene 
EI   electron ionization 
Elk1   transcription factor in the cell nucleus, which is activated by ERK1/2 
ELISA   enzyme-linked immunosorbent assay 
ERK   extracellular signal-regulated kinase 
ES   electrospray ionization 
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Et   ethyl 
EtOAc   ethyl acetate 
EtOH   ethanol 
Et2O   diethylether 
eq.   equivalents 
E. coli   Escherichia coli 
g   gaseous 
g   grams 
Fmoc   fluorenylmethyloxycarbonyl 
h   hours 
HCl   hydrochloric acid 
HClO4   perchloric acid 
HEK   human embryonic kidney cells 
HPLC   high-performance liquid chromatography 
HisF   imidazole glycerol phosphate synthase 
HOBt   hydroxybenzotriazole 
H2O   water 
HP(O)(OEt)2  diethyl phosphite 
HR   high resolution 
Hz   hertz 
ImGP   imidazole glycerol phosphate 
IR   infrared 
J   joule 
J   coupling constant 
K   kelvin 
kcat   apparent unimolecular rate constant 
Ki   inhibition constant 
KM   Michaelis constant 
KOtBu   potassium tert-butoxide 
L   liters 
   wavelength 
LAH   lithium aluminium hydride 
LiI   lithium iodide 
M   molar 
m meters 
m multiplet 
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MAPK mitogen-activated protein kinase 
Me methyl 
MeCN   acetonitrile 
MD molecular dynamics 
MeOD deuterated methanol 
MeOH methanol 
MgSO4 magnesium sulfate 
min minutes 
mol   mole 
m.p.   melting point 
MS   mass spectrometry 
mtPriA   phosphoribosyl-isomerase A from Mycobacterium tuberculosis 
m/z   mass to charge 
N   normal 
 ̃   wavenumber 
n.a.   not available 
NaCl   sodium chloride 
Na2CO3 sodium dicarbonate 
NaHCO3 sodium hydrogen carbonate 
NaOH   sodium hydroxide 
NBS N-bromosuccinimide 
nBuLi n-butyl lithium 
NEt3 triethylamine 
NH4OH aqueous ammonia 
NIR near infrared 
NMR nuclear magnetic resonance 
PCR polymerase chain reaction 
PE petrol ether 
PDB Protein Data Bank 
Pd(OAc)2 palladium(II) acetate 
Pd(PPh3)2Cl2 bis(triphenylphosphine)palladium(II)dichloride 
Pd(PPh3)4 tetrakis(triphenylphosphine)palladium(0) 
POCl3 phosphorous(V) oxychloride 
PPh3 triphenylphosphine 
ppm parts per million 
Appendix 
   
 
 130 
PRFAR N´-[(5´-phosphoribulosyl)-formimino]-5-aminoimidazole-4-
carboxamide-ribonucleotide 
ProFAR N′-[(5′-phosphoribosyl)-formimino]-5-aminoimidazole-4-
carboxamide ribonucleotide 
PS photostationary state 
q quaternary carbon 
Rf retardation factor 
rpm revolutions per minute 
s seconds 
s singlet 
SE standard error 
SOCl2 thionyl chloride 
SPPS solid phase peptide synthesis 
r.t. room temperature 
T temperature 
t triplet 
t time 
TBTU O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
tetrafluoroborate  
TICT twisted intramolecular charge transfer 
TFA trifluoroacetic acid 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
tmHisF   imidazole glycerol phosphate synthase from Thermotoga maritima 
TMS-Br  bromotrimethylsilane 
Tris   tris(hydroxymethyl)aminomethane 
TTN   thallium trinitrate 
UV   ultraviolet 
Vis   visible light 
W   watt 
Å   Ångström 
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